[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 96 of about 96
1. Law YM, Quek ST, Tan PH, Wong SL: Adenoid cystic carcinoma of the breast. Singapore Med J; 2009 Jan;50(1):e8-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm that constitutes less than one percent of all mammary carcinomas.
  • In contrast to the aggressive nature of adenoid cystic carcinoma that occurs in the head and neck region, adenoid cystic carcinoma of the breast has a very favourable prognosis.
  • We describe a 63-year-old woman with adenoid cystic carcinoma detected on mammography in our national breast screening programme, the radiological findings at presentation, the surgical management and a review of the literature.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Mammography. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224074.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 11
  •  go-up   go-down


2. Sheen-Chen SM, Eng HL, Chen WJ, Cheng YF, Ko SF: Adenoid cystic carcinoma of the breast: truly uncommon or easily overlooked? Anticancer Res; 2005 Jan-Feb;25(1B):455-8
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast: truly uncommon or easily overlooked?
  • BACKGROUND: Adenoid cystic carcinoma of the breast is an uncommon histologic form of breast cancer, comprising in most series less than 1% of all mammary cancers.
  • No obvious palpable mass of breast was found on physical examination.
  • Mammography showed a small well-defined nodule in the medial part of the left breast without mammographic evidence of malignancy.
  • Ultrasonography showed a 1.5 cm nodule with well-defined margin and heterogenous echogenicity in the medial part of the left breast.
  • The final pathological report was adenoid cystic carcinoma.
  • No obvious palpable mass of breast was found on physical examination.
  • Mammography showed dense mammary tissue with no mammographic evidence of malignancy.
  • Ultrasonography showed two contiguous well-defined nodules with heterogenous echogenicity in the upper, middle part of the left breast.
  • Histopathological examination showed typical features of an adenoid cystic carcinoma.
  • CONCLUSION: Adenoid cystic carcinoma of the breast fails to show the typical appearance of invasive ductal carcinoma on both mammogram and ultrasonography, probably due to its relatively well-defined nature with less surrounding architectural disruption and fibrosis.
  • Hence a "negative" finding or a benign-looking breast lesion on mammography cannot completely exclude the existence of this disease.
  • The presence of a painful breast lesion without obvious inflammatory evidence while compressed is a meaningful clue, which should lead to the suspicion of adenoid cystic carcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Mammography / methods
  • [MeSH-minor] Aged. Breast / pathology. Female. Humans. Image Processing, Computer-Assisted. Pain. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816611.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Pandya AN, Shah P, Patel R, Patel PR: Adenoid cystic carcinoma of breast and the importance of differentiation from collagenous spherulosis by FNAC. J Cytol; 2010 Apr;27(2):69-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of breast and the importance of differentiation from collagenous spherulosis by FNAC.
  • We are presenting a case of adenoid cystic carcinoma (ACC) of breast in a 66-year-old woman having lump in left breast, admitted to surgical ward of our institute.
  • A diagnosis of ACC of breast was made and subsequently confirmed histopathologically and on immunohistochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157554.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3001180
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / FNAC / breast, collagenous spherulosis
  •  go-up   go-down


Advertisement
4. Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, Rosty C, Klijanienko J, Sigal-Zafrani B, Salmon R, Fourquet A, Sastre-Garau X, Vincent-Salomon A: KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol; 2005 Dec;18(12):1623-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome.
  • Recent biological studies have classified breast carcinomas into HER2-overexpressing, estrogen receptor-positive/luminal, basal- and normal-like groups.
  • According to this new biological classification, the objectives of our study were to assess the clinical, morphologic and immunophenotypic characteristics of adenoid cystic carcinoma of the breast in order to classify this subtype of breast carcinoma.
  • A total of 18 cases of adenoid cystic carcinoma were identified from the Institut Curie files.
  • Our study shows that adenoid cystic carcinoma of the breast is a special, estrogen receptor, progesterone receptor, HER-2 negative and highly KIT-positive, basal-like breast carcinoma, associated with an excellent prognosis.
  • This highly specific immunophenotype could be useful to differentiate adenoid cystic carcinoma of the breast from other subtypes of breast carcinoma such as cribriform carcinoma.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Adenoid Cystic / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258515.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


5. Mastropasqua MG, Maiorano E, Pruneri G, Orvieto E, Mazzarol G, Vento AR, Viale G: Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol; 2005 Oct;18(10):1277-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast.
  • Adenoid cystic carcinoma of the breast represents a unique clinicopathologic entity with a variable histological appearance and a relatively indolent clinical course in most of the cases.
  • Adenoid cystic carcinoma may be difficult to differentiate from infiltrating duct carcinomas, and in particular from tubular and cribriform carcinomas, especially in core or vacuum-assisted biopsies.
  • We evaluated the prevalence of c-kit, p63, and e-cadherin immunoreactivity in a series of 20 adenoid cystic carcinomas, comparing the results with those obtained in a series of infiltrating tubular carcinomas and infiltrating cribriform carcinomas.
  • Three (15%) adenoid cystic carcinomas and all infiltrating tubular and cribriform carcinomas showed estrogen receptor and/or progesterone receptor immunoreactivity (P < 0.00001 for estrogen and P = 0.00002 for progesterone receptors).
  • Adenoid cystic carcinomas consistently lacked any immunoreactivity for HER/2, whereas three (15%) infiltrating and cribriform carcinomas showed weak and incomplete membrane staining (P = 0.23077).
  • Membranous immunoreactivity for c-kit was found in all except one (predominantly basaloid) adenoid cystic carcinomas (95%), and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • Nuclear immunoreactivity for p63 was found in all except three (predominantly basaloid) adenoid cystic carcinomas (85%) and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • All infiltrating tubular and cribriform carcinomas and 18/20 (90%) adenoid cystic carcinomas showed immunoreactivity for e-cadherin (P = 0.48718).
  • In summary, adenoid cystic carcinomas showed the following phenotype: estrogen receptor-/progesterone receptor-/c-kit+/p63+ (13 cases, 65%), estrogen receptor-/progesterone receptor/c-kit+/p63- (three cases, 15%), estrogen receptor-/progesterone receptor-/c-kit-/p63+ (one case, 5%), estrogen receptor+/progesterone receptor+/c-kit+/p63+ (two cases, 10%), and estrogen receptor+/progesterone receptor-/c-kit+/p63+ (one case).
  • Our data provide evidence that immunoreactivity for c-kit and/or p63 may be useful in differentiating adenoid cystic carcinomas from other types of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Membrane Proteins / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846389.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cadherins; 0 / Membrane Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


6. Soon SR, Yong WS, Ho GH, Wong CY, Ho BC, Tan PH: Adenoid cystic breast carcinoma: a salivary gland-type tumour with excellent prognosis and implications for management. Pathology; 2008 Jun;40(4):413-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic breast carcinoma: a salivary gland-type tumour with excellent prognosis and implications for management.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18446636.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Hodgson NC, Lytwyn A, Bacopulos S, Elavathil L: Adenoid cystic breast carcinoma: high rates of margin positivity after breast conserving surgery. Am J Clin Oncol; 2010 Feb;33(1):28-31
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic breast carcinoma: high rates of margin positivity after breast conserving surgery.
  • INTRODUCTION: Adenoid cystic carcinoma of the breast (ACCB) is a rare malignancy with favorable prognosis: axillary lymph node involvement, distant metastases, and death due to disease are uncommon.
  • METHODS: Pathology database searched to identify patients diagnosed with ACCB between 1988 and 2007 at Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.Two pathologists independently reviewed histology to confirm diagnosis of ACCB, and documented surgical procedure, tumor size, tumor grade, surgical margin, and lymph node status.
  • Seven patients presented with a palpable mass and breast pain was described in 3.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Mastectomy. Mastectomy, Segmental. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730354.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Crisi GM, Marconi SA, Makari-Judson G, Goulart RA: Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol; 2005 Nov;124(5):733-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in adenoid cystic carcinoma of the breast.
  • Breast adenoid cystic carcinoma (BACC) is a biologically distinct tumor with morphologic mimickers, which might make accurate classification problematic.
  • Because c-kit expression has been reported in adenoid cystic carcinoma of various anatomic sites, we evaluated BACC for c-kit by immunohistochemical analysis, comparing the findings to similarly stained mimickers.
  • Tested cases included 6 BACCs, 15 low-grade infiltrating ductal carcinomas (LGIDCs) chosen as potential mimickers, and 15 head-neck adenoid cystic carcinomas (HNACCs).
  • Immunohistochemical evaluation for c-kit might aid in accurately classifying carcinomas with histologic features overlapping adenoid cystic carcinoma and LGIDC.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203286.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Kallel R, Bahri Zouari I, Gouiaa N, Charfi S, Daoud E, Ayadi L, Makni S, Daoud J, Sellami Boudawara T: [Adenoid cystic carcinoma of the breast]. Cancer Radiother; 2009 Jul;13(4):323-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinome adénoïde kystique du sein.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm, accounting for only 0.1% of all malignant breast tumours.
  • The preoperative diagnosis is possible with fine-needle aspiration cytology.
  • The diagnosis is made by histological examination, presented a difficult differential diagnosis with cribriform carcinoma; so it is necessary to use histochemical or immunohistochemical techniques.
  • Compared to other locations, adenoid cystic carcinoma of the breast has a favorable prognosis.
  • The aim of our study is to describe the epidemiological, clinicopathological characteristics, the treatment and the prognosis of this rare type of breast tumour.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Combined Modality Therapy / methods. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464219.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


10. Njeze GE: Adenoid cystic carcinoma of the breast at Enugu Nigeria. Niger J Clin Pract; 2007 Mar;10(1):70-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast at Enugu Nigeria.
  • BACKGROUND: (Adenoid cystic carcinoma (ACC) of the breast is a rare type of neoplasm that is histologically indistinguishable from other examples in other sites and generally has a good prognosis).
  • PATIENTS AND METHODS: Case notes of breast cancer patients stored in the medical records department were retrospectively reviewed with a view to studying those with ACC.
  • RESULT: Adenoid cystic carcinoma of the breast was diagnosed in 9 out of 222 patients treated for cancer of the breast, from 1995-2000.
  • A lump in the breast led to the initial suspicion of a tumor.
  • Some of them had pain in the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668719.001).
  • [ISSN] 1119-3077
  • [Journal-full-title] Nigerian journal of clinical practice
  • [ISO-abbreviation] Niger J Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


11. Da Silva L, Buck L, Simpson PT, Reid L, McCallum N, Madigan BJ, Lakhani SR: Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis. Virchows Arch; 2009 Jan;454(1):107-14
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare tumour.
  • Its recognition as a special type of breast carcinoma is very important because its prognosis is better than the not-otherwise-specified invasive ductal carcinoma and its treatment may not include axillary dissection.
  • Tubular adenosis (TA) is a very rare condition of the breast that is histologically benign; however, it has been described in association with invasive ductal carcinoma.
  • There are scant data regarding the molecular genomic alterations in ACC of the breast and no data has been presented on TA.
  • Herein, we provide a morphological characterisation of TA arising synchronically with ACC in the breast.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / complications. Carcinoma, Adenoid Cystic / pathology. Fibrocystic Breast Disease / complications. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Actins / metabolism. Breast / metabolism. Breast / pathology. Cell Proliferation. DNA, Neoplasm. Female. Genomic Instability / genetics. Humans. Keratin-19 / metabolism. Keratin-7 / metabolism. Middle Aged. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Aug;82(2):187-92 [8863309.001]
  • [Cites] Lab Invest. 2007 May;87(5):430-9 [17372589.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):46-54 [8540608.001]
  • [Cites] Am J Surg Pathol. 1986 Apr;10(4):237-45 [3706610.001]
  • [Cites] Cancer. 1975 Jul;36(1):1-85 [173455.001]
  • [Cites] Cytometry. 1998 Mar 1;31(3):163-73 [9515715.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] J Microsc. 2005 Apr;218(Pt 1):52-61 [15817063.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Breast Cancer Res Treat. 2005 Oct;93(3):189-90 [16142443.001]
  • [Cites] Ann Diagn Pathol. 2004 Feb;8(1):39-42 [15129910.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):119-22 [9504855.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jun;101(6):302-6 [193456.001]
  • [Cites] Lab Invest. 2008 May;88(5):464-73 [18332873.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R4 [17217540.001]
  • [Cites] Semin Diagn Pathol. 2003 Nov;20(4):279-304 [14694981.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):250-8 [8625100.001]
  • [Cites] Histopathology. 1987 Mar;11(3):305-15 [2828217.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):544-52 [18300793.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1052-60 [12883237.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R65 [17910759.001]
  • [Cites] Am J Clin Pathol. 1993 Nov;100(5):507-13 [7504394.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Surg Gynecol Obstet. 1966 Jun;122(6):1289-94 [5941852.001]
  • [Cites] Int Semin Surg Oncol. 2006 Jun 30;3:17 [16813652.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):303-315 [11494007.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):99-109 [8422116.001]
  • [Cites] Breast Cancer Res Treat. 2004 Oct;87(3):225-32 [15528965.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):731-7 [6660348.001]
  • [Cites] Histopathology. 1983 Mar;7(2):169-80 [6852780.001]
  • [Cites] Cancer. 1969 Oct;24(4):740-5 [4309694.001]
  • [Cites] J Clin Pathol. 1975 Aug;28(8):647-55 [171285.001]
  • [Cites] Am J Surg Pathol. 1983 Mar;7(2):137-44 [6859388.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):782-9 [10741697.001]
  • [Cites] Am J Clin Pathol. 1973 May;59(5):653-8 [4349849.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Eur J Cancer. 1995 Dec;31A(13-14):2289-95 [8652258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 19031084.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / DNA, Neoplasm; 0 / Keratin-19; 0 / Keratin-7; 0 / S100 Proteins
  •  go-up   go-down


12. Coates JM, Martinez SR, Bold RJ, Chen SL: Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast. J Surg Oncol; 2010 Sep 15;102(4):342-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiation therapy is associated with improved survival for adenoid cystic carcinoma of the breast.
  • BACKGROUND: The role of adjuvant radiation therapy (RT) for adenoid cystic carcinoma (ACC) of the breast remains unclear.
  • MATERIALS AND METHODS: We queried the Surveillance, Epidemiology, and End Results database for patients with breast ACC resected between 1988 and 2005, and divided patients based on the receipt of RT.
  • CONCLUSIONS: RT after local surgical therapy for ACC of the breast improved both cause-specific and overall survival.
  • [MeSH-major] Breast Neoplasms / radiotherapy
  • [MeSH-minor] Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / radiotherapy. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20589709.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Vranić S, Bilalović N, Lee LM, Kruslin B, Lilleberg SL, Gatalica Z: PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol; 2007 Sep;38(9):1425-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney.
  • Adenoid cystic carcinoma (ACC) of the breast rarely metastasizes and has been associated with excellent prognosis.
  • We describe a patient with renal metastasis of primary breast ACC 5 years after the mastectomy.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / pathology. Cystadenocarcinoma / secondary. Kidney Neoplasms / secondary. Mutation. PTEN Phosphohydrolase / genetics. Phosphatidylinositol 3-Kinases / genetics


14. Rabban JT, Swain RS, Zaloudek CJ, Chase DR, Chen YY: Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers. Mod Pathol; 2006 Oct;19(10):1351-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic overlap between adenoid cystic carcinoma and collagenous spherulosis of the breast: potential diagnostic pitfalls using myoepithelial markers.
  • Adenoid cystic carcinoma of the breast is a rare neoplasm whose cribriform architecture may mimic invasive cribriform carcinoma, cribriform ductal carcinoma in situ, and collagenous spherulosis.
  • The diagnosis may be even more challenging in needle core biopsies.
  • Immunohistochemical expression of p63 and c-kit distinguishes adenoid cystic carcinoma from invasive cribriform carcinoma and ductal carcinoma in situ.
  • A formal comparison of the immunophenotype of adenoid cystic carcinoma to collagenous spherulosis has not been reported.
  • We evaluated smooth muscle actin, p63, calponin, smooth muscle myosin heavy chain, as well as c-kit, in nine cases of cribriform pattern adenoid cystic carcinoma of the breast in comparison to 12 cases of collagenous spherulosis.
  • Both entities strongly expressed p63 and smooth muscle actin; in adenoid cystic carcinoma, the basaloid myoepithelial-like tumor cells expressed these markers, but the ductular epithelial cells did not.
  • Neither calponin nor smooth muscle myosin heavy chain was expressed in adenoid cystic carcinoma but both were strongly expressed in collagenous spherulosis.
  • Whereas the ductular epithelial cells of adenoid cystic carcinoma were positive for c-kit in all cases, collagenous spherulosis was negative for c-kit.
  • Positive p63 expression by a cribriform breast lesion is not sufficiently specific to confirm a diagnosis of adenoid cystic carcinoma.
  • Reliance on p63 or smooth muscle actin alone poses a potential diagnostic pitfall in evaluating cribriform breast lesions.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Collagen. Epithelial Cells / pathology
  • [MeSH-minor] Actins / analysis. Calcium-Binding Proteins / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Membrane Proteins / analysis. Microfilament Proteins / analysis. Myosin Heavy Chains / analysis. Proto-Oncogene Proteins c-kit / analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810311.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Calcium-Binding Proteins; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / calponin; 9007-34-5 / Collagen; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


15. Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM: Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res; 2010;12(4):R54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study.
  • INTRODUCTION: Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and special type of basal-like tumor for which scant population-based descriptive data exist.
  • We sought to provide new population-based information on breast-ACC incidence, relative survival, and associated cancer risk in the United States.
  • METHODS: Using data from the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted incidence rates (IRs), IR ratios (IRRs), and relative survival for breast-ACC, and standardized incidence ratios (SIRs) for other cancers.
  • RESULTS: Overall 338 women (IR = 0.92/1 million person-years) were diagnosed with breast-ACC during 1977 to 2006.
  • The risk of female breast cancer was not increased following (SIR = 0.89, 95% confidence interval = 0.43 to 1.64) or preceding (SIR = 0.71, 95% confidence interval = 0.28 to 1.46) breast-ACC.
  • Similarly, no association was observed for breast-ACC and risk of all other cancers combined, solid tumors, or lymphohematopoietic malignancies.
  • CONCLUSIONS: Breast-ACC among women is characterized by ER-negative/PR-negative expression, rare regional lymph node involvement, a favorable prognosis with excellent survival, and absence of associated cancers.
  • These findings reinforce the importance of tailored treatments for breast-ACC and lend credence to the apparent heterogeneity of basal-like breast cancers.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pol Med J. 1970;9(5):1140-8 [4324184.001]
  • [Cites] Pathol Eur. 1970;5(3):357-64 [4320056.001]
  • [Cites] J Clin Pathol. 1975 Aug;28(8):647-55 [171285.001]
  • [Cites] Surg Gynecol Obstet. 1979 Feb;148(2):240-2 [217114.001]
  • [Cites] J Natl Med Assoc. 1979 Apr;71(4):329-30 [220431.001]
  • [Cites] Hum Pathol. 1982 Oct;13(10):916-24 [6290368.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):680-6 [6305483.001]
  • [Cites] Am J Clin Pathol. 1984 Mar;81(3):297-307 [6322567.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):470-2 [3020724.001]
  • [Cites] Ann Surg. 1987 Mar;205(3):295-301 [3030200.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1589-98 [2441847.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Pathol Annu. 1989;24 Pt 2:237-54 [2549491.001]
  • [Cites] Arch Surg. 1992 Feb;127(2):233-5 [1311551.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):215-9 [8685217.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):569-75 [9591727.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1679-83 [9843312.001]
  • [Cites] Histopathology. 1999 Sep;35(3):241-8 [10469216.001]
  • [Cites] Dis Chest. 1957 Mar;31(3):324-7 [13404914.001]
  • [Cites] Breast Cancer Res Treat. 2004 Oct;87(3):225-32 [15528965.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4514-22 [15542802.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):455-8 [15816611.001]
  • [Cites] Am J Clin Pathol. 2005 Jun;123(6):866-73 [15899777.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1277-82 [15846389.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):733-9 [16203286.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1733-41 [16138363.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Breast Cancer. 2006;13(1):112-6 [16518072.001]
  • [Cites] J Ultrasound Med. 2006 Jul;25(7):921-4 [16798905.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1351-7 [16810311.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1899-905 [17035397.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):206 [17319868.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3923-9 [17679726.001]
  • [Cites] Breast Cancer Res. 2007;9(5):R65 [17910759.001]
  • [Cites] Curr Opin Obstet Gynecol. 2008 Feb;20(1):40-6 [18197004.001]
  • [Cites] Can J Surg. 2008 Apr;51(2):E36-7 [18377738.001]
  • [Cites] Pathology. 2008 Jun;40(4):413-5 [18446636.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Virchows Arch. 2009 Jan;454(1):107-14 [19031084.001]
  • [Cites] Singapore Med J. 2009 Jan;50(1):e8-11 [19224074.001]
  • [Cites] Arch Intern Med. 2009 May 25;169(10):999-1000, author reply 1000-1 [19468099.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2214-20 [19661080.001]
  • [Cites] J Clin Pathol. 2010 Mar;63(3):220-8 [20203221.001]
  • [Cites] Breast Cancer. 2001;8(1):84-9 [11180772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Breast J. 2002 Jan-Feb;8(1):53-4 [11856164.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):646-9 [12095593.001]
  • [Cites] Breast. 2003 Feb;12(1):75-7 [14659359.001]
  • [Cites] Semin Diagn Pathol. 2003 Nov;20(4):279-304 [14694981.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83 [14734467.001]
  • [Cites] Pathology. 2004 Aug;36(4):362-4 [15370139.001]
  • [Cites] Surg Gynecol Obstet. 1966 Jun;122(6):1289-94 [5941852.001]
  • [Cites] Ann Surg. 1967 Nov;166(5):861-4 [6057095.001]
  • [Cites] Cancer. 1969 Oct;24(4):740-5 [4309694.001]
  • [Cites] Am J Clin Pathol. 1970 Sep;54(3):419-25 [4319210.001]
  • [Cites] Am J Clin Pathol. 1973 May;59(5):653-8 [4349849.001]
  • (PMID = 20653964.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2949643
  •  go-up   go-down


16. Albores-Saavedra J, Heard SC, McLaren B, Kamino H, Witkiewicz AK: Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. Am J Clin Pathol; 2005 Jun;123(6):866-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast.
  • We compared 4 breast cylindromas with 50 dermal cylindromas and 8 adenoid cystic breast carcinomas.
  • Except for a modest increase in the number of eccrine ducts and reactive Langerhans cells in dermal cylindromas, breast and dermal cylindromas showed identical histologic and immunohistochemical features.
  • Clusters of sebaceous cells and a few eccrine ducts are described in breast cylindromas.
  • Cytokeratin 7 labeled predominantly the central basaloid cells, and smooth muscle actin stained peripheral myoepithelial cells in breast and dermal cylindromas.
  • Cylindromas of the breast and skin did not express cytokeratin 20, gross cystic disease fluid protein 15, or estrogen or progesterone receptor.
  • Breast cylindroma might be confused with the solid variant of adenoid cystic carcinoma, especially in needle core biopsy specimens, because they share nodular and trabecular patterns, basaloid cells, myoepithelial cells, eccrine ducts, and hyaline globules of basement membrane material.
  • However, adenoid cystic carcinoma displays an infiltrative growth pattern, cytologic atypia, and mitotic figures and lacks the continuous, thickened basement membrane.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Sweat Glands / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899777.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


17. Sbitti Y, Kadiri H, Fetohi M, Elghissassi I, M'rabti H, Boutayeb S, Ichou M, Boussen H, Errihani H: [Primary adenoid cystic carcinoma in breast]. Cancer Radiother; 2009 Jan;13(1):65-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenoid cystic carcinoma in breast].
  • [Transliterated title] Carcinome adénoïde kystique primitif du sein.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare neoplasm.
  • Clinical examination showed limited painful breast nodules.
  • Diagnosis was based on final histopathological exam completed by immunohistochemistry or after slides review.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Adenoid Cystic
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Lymph Node Excision. Mammography. Mastectomy. Middle Aged. Physical Examination. Postoperative Care / methods. Prognosis. Radiotherapy, Adjuvant. Rare Diseases. Treatment Outcome. Tunisia. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097926.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


18. Franceschini G, Terribile D, Scafetta I, Magno S, Fabbri C, Chiesa F, Di Leone A, Moschella F, Scaldaferri A, Fragomeni S, Vellone V, Mulè A, Masetti R: Conservative treatment of a rare case of multifocal adenoid cystic carcinoma of the breast: case report and literature review. Med Sci Monit; 2010 Mar;16(3):CS33-39
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of a rare case of multifocal adenoid cystic carcinoma of the breast: case report and literature review.
  • BACKGROUND: Adenoid cystic carcinoma of the breast is a rare neoplasm accounting for 0.1% of all malignant breast tumors and presenting most commonly as a painful breast mass.
  • Compared with the more common histological forms of breast cancer, it has a more favorable prognosis and lymph node involvement or distant metastases seldom occur.
  • CASE REPORT: A unique case of multifocal adenoid cystic carcinoma of the breast presenting as a painful and well-defined lump and treated with conservative surgery with adjuvant radiotherapy is reported.
  • A breast-conserving approach may be recommended even if mastectomy has been traditionally the treatment of choice.
  • The authors found no other reports in the literature focusing on a conservative approach to multifocal adenoid cystic carcinoma.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Adenoid Cystic / therapy

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190690.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 39
  •  go-up   go-down


19. de Luis E, Apesteguía L, Noguera JJ, Pina L, Martínez-Regueira F, Miguel C, Sáenz J: [Adenoid cystic carcinoma of the breast]. Radiologia; 2006 Jul-Aug;48(4):235-40
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast].
  • [Transliterated title] Carcinoma adenoide quístico de mama.
  • OBJECTIVE: To review the clinical presentation and imaging findings of adenoid cystic carcinoma (ACC).
  • MATERIAL AND METHODS: We performed a retrospective study of the period between January 1990 and July 2004, comprising five cases of ACC of the breast, all in women, among 4,036 malignant lesions diagnosed (0.12%).
  • Four patients remain asymptomatic at present (mean follow-up = 64 months) and one presented lung and liver metastes twelve years after the diagnosis of ACC.
  • CONCLUSION: ACC is an uncommon breast tumor with varied radiologic appearance, although moderately or highly suspicious lesions predominate.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058651.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


20. Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z: Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol; 2010 Nov;41(11):1617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
  • Adenoid cystic carcinoma of the breast is a rare subtype of breast cancer with basal-like features.
  • Published studies on breast adenoid cystic carcinoma are limited, resulting in relatively scarce information on the value of predictive tumor markers.
  • We studied 20 primary cases of adenoid cystic carcinoma of the breast for expression of estrogen receptor, progesterone receptor, androgen receptor, epidermal growth factor receptor, HER-2/neu, and topoisomerase IIα using immunohistochemistry and fluorescent in situ hybridization methods.
  • Our study shows that the majority of adenoid cystic carcinomas of the breast do not overexpress Her-2/neu, topoisomerase IIα, or estrogen receptor, and thus, they are unlikely to respond to therapies targeting these proteins.
  • However, these tumors frequently over-express epidermal growth factor receptor, indicating a potential benefit from anti-epidermal growth factor receptor therapy for patients with advanced adenoid cystic carcinomas of the breast.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms, Male / metabolism. Carcinoma, Adenoid Cystic / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Gene Amplification. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20688355.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


21. Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC: Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol; 2010 May;194(5):1391-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast.
  • OBJECTIVE: The purpose of our study was to describe the imaging findings in adenoid cystic carcinoma (ACC) of the breast, with pathologic and clinical correlation.
  • MATERIALS AND METHODS: We retrospectively searched our surgical database from January 1994 through December 2008 for cases of pathologically proven ACC of the breast.
  • Of approximately 15,000 breast biopsies, 11,250 were malignant.
  • MRI (n = 5)--because of better soft-tissue contrast and dedicated, multiplanar breast sequences--helped show the extent of the tumor, particularly if dense breast tissue obscured the mass on CT.
  • On molecular breast imaging (n = 1), the tumors showed avid uptake of radiotracer but did not always show activity on PET (n = 1).
  • CONCLUSION: Recognition of ACC is important to avoid delay in diagnosis because this tumor has a good prognosis with rare metastases to axillary lymph nodes.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / epidemiology. Magnetic Resonance Imaging / methods. Mammography / methods


22. Popa I, Welt L, Constantin G, Popa E, Bordea A, Burcoş T, Iosif C, Angelescu N: [Adenoid cystic carcinoma of the breast--two case reports]. Chirurgia (Bucur); 2010 Nov-Dec;105(6):827-30
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast--two case reports].
  • [Transliterated title] Carcinom adenoid chistic mamar--prezentare a două cazuri.
  • Adenoid cystic carcinoma is a rare type of breast carcinoma with a good prognosis.
  • It represents less than 0,1% of breast carcinomas.
  • We present two cases of adenoid cystic carcinoma diagnosed in the Surgical Department of Coltea Hospital in the last 3 years.
  • The first case is a 66 years old patient with a breast tumor that has clinical and imagistic features compatible with a benign diagnosis.
  • The frozen sections established the diagnosis of adenoid cystic carcinoma, confirmed by histopathologic examination of paraffin embedded tissue and immunohistochemistry.
  • The second case is a 68 years old patient with a breast tumor located in the central quadrant of the left breast, with skin infiltration.
  • The frozen sections established the diagnosis of ductal invasive carcinoma and histopathologic examination of paraffin embedded tissue and immunohistochemistry established the diagnosis of adenoid cystic carcinoma associated with ductal invasive carcinoma grade I and adenomyoepitelioma.
  • [MeSH-major] Adenomyoepithelioma / pathology. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Mastectomy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21355181.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


23. Defaud-Hénon F, Tunon-de-Lara C, Fournier M, Marty M, Velasco V, de Mascarel I, MacGrogan G: [Adenoid cystic carcinoma of the breast: clinical, histological and immunohistochemical characterization]. Ann Pathol; 2010 Feb;30(1):7-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the breast: clinical, histological and immunohistochemical characterization].
  • [Transliterated title] Le carcinome adénoïde kystique du sein: étude clinique, histologique, immunohistochimique et revue de la littérature.
  • BACKGROUND: Adenoid cystic carcinoma (ACC) of the Breast is a rare tumour (less than 1 % of all breast carcinomas).
  • CONCLUSIONS: The mammary ACC is made of two cell types and is of good prognosis despite its triple negative phenotype, similar to the basal-like infiltrating carcinoma NOS.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology


24. Muslimani AA, Ahluwalia MS, Clark CT, Daw HA: Primary adenoid cystic carcinoma of the breast: case report and review of the literature. Int Semin Surg Oncol; 2006;3:17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenoid cystic carcinoma of the breast: case report and review of the literature.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare neoplasm accounting for 0.1% of all breast carcinomas, and presenting most commonly as a painful breast mass.
  • In contrast to the aggressive nature of ACC at other sites, ACC of the breast has a favorable prognosis, lymph node involvement or distant metastases seldom occur.
  • We report a case of ACC of the breast managed with mastectomy and review the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Jan;25(1):186-98 [4312026.001]
  • [Cites] J Clin Pathol. 1975 Aug;28(8):647-55 [171285.001]
  • [Cites] Am J Clin Pathol. 1970 Sep;54(3):419-25 [4319210.001]
  • [Cites] Am J Clin Pathol. 1970 Jul;54(1):1-14 [4323423.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Breast. 2003 Feb;12(1):75-7 [14659359.001]
  • [Cites] Arch Surg. 1992 Feb;127(2):233-5 [1311551.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jun;101(6):302-6 [193456.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Diagn Cytopathol. 1993;9(2):184-7 [8390344.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):431-4 [8989549.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):646-9 [12095593.001]
  • (PMID = 16813652.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1526742
  •  go-up   go-down


25. Kshirsagar AY, Wader JV, Langade YB, Jadhav KP, Zaware SU, Shekhar N: Adenoid cystic carcinoma of the male breast. Int Surg; 2006 Jul-Aug;91(4):234-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the male breast.
  • We present an 82-year-old male patient who presented with complaints of gradually an increasing ulcero-proliferative lesion with persistent mucinous discharge in the left breast.
  • This was histopathologically diagnosed as an adenoid cystic carcinoma of the left breast.
  • Periodic acid schiff (PAS) staining confirmed the diagnosis.
  • [MeSH-major] Breast Neoplasms, Male / surgery. Carcinoma, Adenoid Cystic / surgery

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967686.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


26. Blanco M, Egozi L, Lubin D, Poppiti R: Adenoid cystic carcinoma arising in a fibroadenoma. Ann Diagn Pathol; 2005 Jun;9(3):157-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma arising in a fibroadenoma.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare neoplasm, accounting for only 0.1 % of all breast carcinomas.
  • An intriguing factor of ACC in the breast is its good prognosis compared to ACC in other locations, mainly in the minor salivary glands.
  • The incidence of axillary lymph node involvement is also very low compared to that of other breast tumors, and distant metastases are uncommon.
  • We report the case of a 65-year-old woman with a 2-year history of a well-circumscribed breast nodule sonographically thought to be a lymph node which was later excised because of rapid growth.
  • Histologic examination showed an adenoid cystic carcinoma with squamous differentiation originating in a fibroadenoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Fibroadenoma / pathology. Neoplasms, Second Primary / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944959.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Cabibi D, Cipolla C, Maria Florena A, Fricano S, Barresi E, Vieni S, Rodolico V, Napoli L: Solid variant of mammary "adenoid cystic carcinoma with basaloid features" merging with "small cell carcinoma". Pathol Res Pract; 2005;201(10):705-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid variant of mammary "adenoid cystic carcinoma with basaloid features" merging with "small cell carcinoma".
  • We describe a rare case of a solid variant of a mammary adenoid cystic carcinoma with basaloid features (sbACC) and its coexistence with a "small cell" carcinoma (SCC), identified and confirmed by histological and immunohistochemical observations: the absence of glandular structures and PAS-positive globules, positivity for neuroendocrine markers (NSE, synaptophysin and chromogranin), and negativity for 34betaE12 and SMA actin were the aspects suggesting the presence of SCC.
  • To our knowledge, this is the first reported case of a solid basaloid adenoid cystic carcinoma merging with an SCC carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Small Cell / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325513.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism


29. Kawamata T, Harashima S, Kubo O, Hori T: Intrasellar remote metastasis from adenoid cystic carcinoma of parotid gland: case report. Endocr J; 2006 Oct;53(5):659-63
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrasellar remote metastasis from adenoid cystic carcinoma of parotid gland: case report.
  • Adenoid cystic carcinoma is a tumor of exocrine glands originating primarily from the minor and major salivary glands, lacrimal gland, bronchus, breast, and intestinal and genital tracts.
  • Intracranial remote metastasis from adenoid cystic carcinoma in salivary gland is quite rare.
  • The authors encountered a case of intrasellar remote metastasis from an adenoid cystic carcinoma of parotid gland origin, presenting with hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
  • To our knowledge, this is the first reported case of metastasis from an adenoid cystic carcinoma to intrasellar area.
  • A 78-year-old woman had an adenoid cystic carcinoma in the left parotid gland, which was resected surgically followed by local radiation therapy of 60 Gy.
  • Histopathological examination of the tumor specimens revealed adenoid cystic carcinoma, which had identical histological findings as those of the painful superficial cervical lymph nodes resected in the same operation.
  • Although rare, metastasis from tumors including those of salivary gland origin should be considered in the differential diagnosis of unusual pituitary tumors.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Parotid Neoplasms / pathology. Pituitary Neoplasms / secondary. Sella Turcica

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16902261.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


30. Noske A, Schwabe M, Pahl S, Fallenberg E, Richter-Ehrenstein C, Dietel M, Kristiansen G: Report of a metaplastic carcinoma of the breast with multi-directional differentiation: an adenoid cystic carcinoma, a spindle cell carcinoma and melanoma. Virchows Arch; 2008 May;452(5):575-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of a metaplastic carcinoma of the breast with multi-directional differentiation: an adenoid cystic carcinoma, a spindle cell carcinoma and melanoma.
  • Metaplastic carcinoma of the breast is a heterogeneous neoplasia, generally composed of both epithelial and mesenchymal components.
  • We report an unusual case of mammary metaplastic carcinoma in a 51-year-old female patient.
  • The resection specimen revealed a multi-directional tumour differentiation consisting predominantly of: firstly, a poorly differentiated basaloid epithelial cell type, consistent with an adenoid cystic carcinoma; secondly, areas of a spindle cell carcinoma; and, thirdly, areas with a melanocytic differentiation.
  • This is the first report on a metaplastic carcinoma of the breast presenting as an admixture of an adenoid cystic carcinoma and melanoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma, Adenoid Cystic / pathology. Cell Transformation, Neoplastic / pathology. Melanoma / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Humans. Metaplasia / diagnosis. Metaplasia / pathology. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):173-8 [15868445.001]
  • [Cites] Cancer. 1984 May 1;53(9):1908-17 [6322962.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2515-25 [8952560.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):592-6 [9195577.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):497-506 [12835294.001]
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1280-7 [10524531.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Diagn Cytopathol. 2000 Jul;23(1):46-50 [10907933.001]
  • [Cites] Histopathology. 2000 Nov;37(5):456-9 [11119128.001]
  • (PMID = 18283489.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Dincer N, Tezel GG, Sungur A, Himmetoglu C, Huebner K, Güler G: Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol; 2010 Mar;46(3):195-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland.
  • Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) are salivary gland neoplasms with divergent morphological features and clinical behavior.
  • In previous studies, we have shown concordant loss of Fhit and Wwox expression in breast cancer, with significantly more frequent loss in cancers of basal-like phenotype.
  • The results suggest that, as for breast cancer, loss of Fhit and Wwox expression might have a role in the pathogenesis of basaloid differentiation in salivary gland neoplasms; alternatively, differences in chromatin structure at chromosome fragile regions might make fragile genes more accessible to DNA damage and rearrangement early during preneoplastic stages of basaloid cancers.
  • [MeSH-major] Acid Anhydride Hydrolases / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Neoplasm Proteins / metabolism. Oxidoreductases / metabolism. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20060354.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; 0 / fragile histidine triad protein; EC 1.- / Oxidoreductases; EC 1.1.1.- / WWOX protein, human; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


32. Kasagawa T, Suzuki M, Doki T, Fujimori T, Itami M, Takenouchi T, Yamamoto N: Two cases of adenoid cystic carcinoma: preoperative cytological findings were useful in determining treatment strategy. Breast Cancer; 2006;13(1):112-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of adenoid cystic carcinoma: preoperative cytological findings were useful in determining treatment strategy.
  • Adenoid cystic carcinoma (ACC) of the breast is a rare variant of breast malignancy and is known to have an excellent prognosis.
  • Considering the characteristics of ACC, breast-conserving surgeries with axillary dissection and adjuvant radiotherapy were performed instead of primary chemotherapy or mastectomy.
  • Even though ACC is very rare, preoperative diagnosis can be made based on its characteristic features.
  • Preoperative diagnosis is extremely useful for determining appropriate treatment.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518072.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H, Zhang Z: Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer; 2007 May 1;120(9):1909-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer.
  • Ebp1, an ErbB3 binding protein and downstream effector of the ErbB signaling network was shown to be a potent tumor suppressor in breast and prostate adenocarcinomas.
  • We hypothesized that the inhibitory properties of the ebp1 gene could also be beneficial if ectopically expressed in salivary adenoid carcinoma.
  • Salivary adenoid carcinoma cell line (ACC-M) cells were stably transfected with the full-length ebp1 cDNA sequence or the empty expression vector pcDNA3.1.
  • Matrigel assays demonstrated that the adenoid cystic carcinoma cell invasiveness was significantly reduced.
  • A strong decrease in the metastatic potential of human adenoid cystic carcinoma cells in an experimental metastatic model was also observed.
  • Our results suggest that ectopic expression of Ebp1 mediates multiple antitumor activities against adenoid cystic carcinoma cells and that ebp1 gene therapy might be a viable method suppressing malignant salivary adenoid tumors.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Carcinoma, Adenoid Cystic / therapy. Genetic Therapy. Receptor, ErbB-3 / metabolism. Salivary Gland Neoplasms / therapy


34. Alves SM, Cardoso SV, de Fátima Bernardes V, Machado VC, Mesquita RA, Vieira do Carmo MA, Ferreira Aguiar MC: Metallothionein immunostaining in adenoid cystic carcinomas of the salivary glands. Oral Oncol; 2007 Mar;43(3):252-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein immunostaining in adenoid cystic carcinomas of the salivary glands.
  • Metallothionein (MT) is a protein that has been studied in several tumors as a prognostic factor and as a potential myoepithelial cell marker in breast cancer.
  • The aims of this study were to assess the immunohistochemical staining of MT in adenoid cystic carcinomas of the salivary glands (ACC), and to analyze possible morphological and quantitative variations among the solid, cribriform, and tubular histological subtypes.
  • [MeSH-major] Carcinoma, Adenoid Cystic / chemistry. Metallothionein / analysis. Neoplasm Proteins / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857408.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9038-94-2 / Metallothionein
  •  go-up   go-down


35. Masih I, Porter G, Porter S, Clarke R, Sidhu P, Harney J, McCarthy A, Convery R: Primary adenoid cystic carcinoma of the bronchus in a female teenager. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenoid cystic carcinoma of the bronchus in a female teenager.
  • Primary adenoid cystic carcinoma (ACC) of the lung is an extremely rare malignant lung neoplasm.
  • ACC of salivary glands of the head and neck, lachrymal glands, breast, skin, vulva and trachea have been frequently reported disease patterns in the literature, but it is unique to see this rare lung tumour in a patient as young as 14 years old.
  • Our report of primary lung ACC in a young girl is a complex case due to young age, a different way of presentation and staging on diagnosis.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1984 Oct;88(4):511-8 [6090818.001]
  • [Cites] Arch Bronconeumol. 1999 Jun;35(6):257-60 [10410204.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1390-7 [7509254.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2002 Apr;8(2):74-7 [12027791.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):273-80 [9648155.001]
  • [Cites] Chest. 1991 Nov;100(5):1464-5 [1657541.001]
  • [Cites] Oncology. 2000;58(1):15-7 [10644935.001]
  • [Cites] Thorax. 1993 Jul;48(7):688-92 [8153914.001]
  • (PMID = 22798097.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC3027792
  •  go-up   go-down


36. Marchiò C, Weigelt B, Reis-Filho JS: Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol; 2010 Mar;63(3):220-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).
  • Adenoid cystic carcinoma (AdCC) is a tumour with myoepithelial differentiation and characterised by the presence of a dual population of basaloid and luminal cells arranged in specific growth patterns.
  • However, the clinical behaviour of salivary gland and breast AdCC differs; while salivary gland lesions have a relatively high proclivity to metastasise, patients with breast AdCCs have an excellent outcome.
  • Here the clinical, morphological and molecular features, and potential therapeutic targets of salivary gland and breast AdCCs are reviewed.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20203221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 113
  •  go-up   go-down


37. Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O: Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One; 2009;4(6):e6040
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2.
  • Adenoid cystic carcinoma (ACC) is the second most common malignant neoplasm of the salivary glands.
  • [MeSH-major] Carcinoma, Adenoid Cystic / classification. Carcinoma, Adenoid Cystic / genetics. Cell Line, Tumor. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Salivary Gland Neoplasms / classification. Salivary Gland Neoplasms / genetics

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Sep 15;86(6):928-35 [10491517.001]
  • [Cites] J Forensic Sci. 1998 Nov;43(6):1168-80 [9846394.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] FASEB J. 2005 Mar;19(3):434-6 [15637111.001]
  • [Cites] Ear Nose Throat J. 2005 Oct;84(10):662, 664-7 [16382750.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Zhonghua Kou Qiang Yi Xue Za Zhi. 2006 Jun;41(6):358-9 [16836907.001]
  • [Cites] Oncol Rep. 2007 Feb;17(2):335-40 [17203170.001]
  • [Cites] Science. 2007 Feb 16;315(5814):928-31 [17303729.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):988-94 [17234357.001]
  • [Cites] Biologicals. 2007 Jun;35(3):195-202 [17254797.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):13-9 [17004106.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):1-4 [17960586.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2007 Nov-Dec;43(10):344-51 [17934781.001]
  • [Cites] Biotechniques. 2007 Nov;43(5):575, 577-8, 581-2 passim [18072586.001]
  • [Cites] Cell Biol Toxicol. 2007 Nov;23(6):367-72 [17522957.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5081-9 [18698025.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):37-45 [10653001.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Nov-Dec;35(10):558-9 [10614862.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):248-52 [10745180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Br J Plast Surg. 2001 Sep;54(6):476-80 [11513507.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2001 Sep;37(8):505-14 [11669284.001]
  • [Cites] Biotechniques. 2002 Feb;32(2):432-4, 436, 438-40 [11848419.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):315-9 [12001993.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):120-7 [12127396.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6981-9 [12460916.001]
  • [Cites] Leukemia. 2003 Feb;17(2):416-26 [12592342.001]
  • [Cites] Proc Biol Sci. 2003 Aug 7;270 Suppl 1:S96-9 [12952648.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):127-32 [15167050.001]
  • [Cites] Nature. 1968 Feb 24;217(5130):750-1 [5641128.001]
  • [Cites] Int J Cancer. 1973 May;11(3):765-73 [4133950.001]
  • [Cites] Science. 1981 Apr 24;212(4493):446-52 [6451928.001]
  • [Cites] Nature. 1983 Feb 3;301(5899):429-30 [6823318.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Mar;26(3 Pt 1):265-74 [1690702.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):4139-45 [2162254.001]
  • [Cites] Zhonghua Kou Qiang Yi Xue Za Zhi. 1990 Jan;25(1):29-31, 62 [2163817.001]
  • [Cites] Pathol Res Pract. 1990 Oct;186(5):555-81 [1962854.001]
  • [Cites] Biotechniques. 1995 Jan;18(1):62-3 [7702855.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Apr;26(2):116-9 [9151166.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Jan;34(1):1-8 [9542623.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):555-63 [10508494.001]
  • (PMID = 19557180.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.9.3.1 / Electron Transport Complex IV
  • [Other-IDs] NLM/ PMC2698276
  •  go-up   go-down


38. Zhang J, Peng B: In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer; 2007;7:95
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma.
  • BACKGROUND: Adenoid cystic carcinoma is a high malignant carcinoma characterized by intensive local invasion and high incidence of distant metastasis.
  • Although many reports have demonstrated that angiogenesis has played an important role in tumor metastasis, the relationship between metastasis characters and angiogenesis ability in high and low metastasis cell lines of Adenoid cystic carcinoma has rarely been reported.
  • [MeSH-major] Carcinoma, Adenoid Cystic / blood supply. Carcinoma, Adenoid Cystic / secondary. Neovascularization, Pathologic / pathology. Salivary Gland Neoplasms / blood supply. Transcription Factor RelA / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2000 Mar 15;346 Pt 3:793-8 [10698708.001]
  • [Cites] BMC Cancer. 2006;6:110 [16650286.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5334-9 [11034066.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):77-83 [11120487.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7048-51 [11585733.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3037-44 [11753981.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jun;73(3):237-43 [12160329.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):883-8 [12213582.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6837-45 [12460896.001]
  • [Cites] FASEB J. 2002 Dec;16(14):1928-30 [12368225.001]
  • [Cites] Cell Res. 2002 Dec;12(5-6):311-20 [12528889.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):346-54 [12538487.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21631-8 [12690099.001]
  • [Cites] Oral Oncol. 2004 Apr;40(4):400-8 [14969819.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2501-5 [9059339.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Apr;26(2):116-9 [9151166.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):495-8 [9374223.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7334-43 [16243805.001]
  • [Cites] Angiogenesis. 2005;8(4):349-60 [16400520.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):209-23 [16530705.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):446-55 [16615157.001]
  • [Cites] Cell Signal. 2000 Mar;12(3):123-33 [10704819.001]
  • (PMID = 17543095.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transcription Factor RelA; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1903362
  •  go-up   go-down


39. Mateş IN, Dinu D, Iosif C, Anghelescu L, Constantinoiu S: [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer]. Chirurgia (Bucur); 2007 Jul-Aug;102(4):471-9
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simultaneous bilateral breast carcinoma--case study and review of primitive bilateral breast cancer].
  • [Transliterated title] Carcinom mamar bilateral, simultan. Studiu de caz şi review asupra cancerului mamar bilateral primitiv.
  • Bilateral breast cancer is uncommon and difficult to define because it may manifest as simultaneous, synchronous or metachronous tumours.
  • Following a right breast contusion, bilateral breast tumours were diagnosed in a 74 old female patient; the left one, neglected for 3 years, typically scirrous; the right one with cystic, pseudo-inflammatory appearance.
  • Sonography and fine-needle cytology concluded: left, carcinoma (T3bN1Mx); right, benign nodule with traumatic hematoma.
  • Histopathology: left, invasive lobular carcinoma (ypT4N0Mx); right, micropapillary invasive carcinoma mixed with adenoid cystic carcinoma.
  • Based on clinical, epidemiologic, morphologic and genetic evidence, bilateral breast cancers (synchronous or metachronous) are considered to be a special evolutive entity of breast cancer.
  • Our case suggests that, in the absence of risk factors for bilaterality of breast carcinoma: description of bilateral breast cancers based on diagnostic chronology of the two tumours is arbitrary; they may occur sporadically and have independent evolution; their biology rather resembles a multiple primitive malignancy than a true bilateral breast cancer.
  • [MeSH-major] Breast Neoplasms. Carcinoma. Mastectomy. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966947.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 58
  •  go-up   go-down


40. Otterbach F, Schmid KW: [Salivary gland-like tumors of the breast]. Pathologe; 2006 Sep;27(5):363-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salivary gland-like tumors of the breast].
  • A subset of rare benign and malignant breast tumors with and without myoepithelial differentiation are morphologically and histogenetically similar to salivary gland tumors, but may differ in incidence and clinical behavior.
  • The clinicopathological, immunohistochemical, molecular and prognostic features of ten salivary gland-like tumor entities of the breast are discussed and compared with their respective counterparts in the salivary glands.
  • [MeSH-major] Breast Neoplasms / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Carcinoma, Adenoid Cystic / pathology. Cell Differentiation. Female. Humans. Myoepithelioma / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2003 Aug;120(2):161-7 [12931544.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2119-27 [12001107.001]
  • [Cites] Breast J. 2004 Sep-Oct;10(5):443-7 [15327500.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] Curr Top Pathol. 1970;53:161-220 [4323195.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):795-801 [2161180.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):179-91 [14712223.001]
  • [Cites] Virchows Arch. 1996 Sep;429(1):69-74 [8865856.001]
  • [Cites] Virchows Arch. 2004 Jan;444(1):13-9 [14634807.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] J Pathol. 2004 Mar;202(3):274-85 [14991892.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):545-7 [12101208.001]
  • [Cites] J Pathol. 2005 Aug;206(4):451-7 [15906273.001]
  • [Cites] ANZ J Surg. 2004 Dec;74(12):1135-7 [15574167.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e155-6 [12653606.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] Am J Surg Pathol. 1993 Mar;17(3):248-58 [8434705.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):497-506 [12835294.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Jun 23;374(3):263-9 [196390.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):554-68 [1709559.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):303-10 [9565338.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):119-22 [9504855.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1206-14 [1660850.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):74-81 [10963383.001]
  • [Cites] Semin Diagn Pathol. 2003 Nov;20(4):279-304 [14694981.001]
  • [Cites] Am J Surg Pathol. 1987 May;11(5):351-8 [3578645.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):158-66 [10755607.001]
  • [Cites] Virchows Arch. 2002 May;440(5):536-42 [12021929.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):792-4 [2161179.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] BMC Cancer. 2005 Jul 28;5:92 [16050957.001]
  • [Cites] Med Hypotheses. 1997 Jan;48(1):37-46 [9049988.001]
  • [Cites] Pathol Int. 1995 Jun;45(6):441-7 [7581936.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):347-53 [15725803.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1277-82 [15846389.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):285-8 [9769134.001]
  • [Cites] Cancer. 1991 May 1;67(9):2350-5 [2013041.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):632-6 [10747327.001]
  • [Cites] Histopathology. 2000 Mar;36(3):286-9 [10809602.001]
  • [Cites] Tunis Med. 2004 Mar;82(3):324-8 [15382470.001]
  • [Cites] J Pathol. 2002 Dec;198(4):487-94 [12434418.001]
  • [Cites] Virchows Arch. 2005 Feb;446(2):142-9 [15583933.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1045-53 [3022669.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;422(2):153-9 [8385380.001]
  • (PMID = 16896677.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Khalbuss WE: Cytomorphology of rare malignant tumors of the breast. Clin Lab Med; 2005 Dec;25(4):761-75, vii
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of rare malignant tumors of the breast.
  • This article reviews cytomorphology of rare malignant tumors of the breast: squamous carcinoma, metaplastic carcinoma, adenoid cystic carcinoma, apocrine carcinoma, secretory carcinoma, lipid-rich carcinoma, and carcinoma with choriocarcinomatous features.
  • It is important to bear in mind the cytomorphology and diagnosis of rare malignant tumors of the breast in analysis of breast fine needle aspiration smears.
  • Although rare, these malignant tumors can be diagnosed by the cytomorphological characteristics, and should be included in the differential diagnoses of breast neoplasms.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308090.001).
  • [ISSN] 0272-2712
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


42. Han B, Mori I, Nakamura M, Wang X, Ozaki T, Nakamura Y, Kakudo K: Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis. Pathol Int; 2006 Apr;56(4):211-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis.
  • Adenomyoepithelioma (AME) of the breast is an uncommon tumor characterized by biphasic proliferation of both epithelial and myoepithelial cells.
  • Described herein is the case of a 69-year-old woman who presented with myoepithelial carcinoma of the breast in an AME.
  • To the authors' knowledge this is the first report of a mutation in the p53 gene in a malignant AME of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Myoepithelioma / pathology. Neoplasms, Multiple Primary / pathology. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16634967.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


43. Lamovec J, Falconieri G, Salviato T, Pizzolitto S: Basaloid carcinoma of the breast: a review of 9 cases, with delineation of a possible clinicopathologic entity. Ann Diagn Pathol; 2008 Feb;12(1):4-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid carcinoma of the breast: a review of 9 cases, with delineation of a possible clinicopathologic entity.
  • Basaloid carcinoma of the breast (BCB) is an unusual neoplasm composed of basal-type neoplastic cells similar to those found in adenoid cystic carcinoma (ACC), although lacking distinctive features such as a cribriform pattern, a dual neoplastic population (epithelial-myoepithelial/basaloid), and stromal deposits of basement membrane-like material.
  • In this article, we present 9 cases of breast cancer showing overall/predominant basaloid morphology.
  • Transition into pleomorphic basaloid carcinoma with foci of high-grade ductal carcinoma in situ plus infiltrating ductal carcinoma (IDC) and admixture with grade 3 ductal and sarcomatoid carcinoma was seen in 2 cases.
  • At follow-up (range, 10-169 months), 5 patients were alive, 1 with evidence of contralateral breast cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Transitional Cell / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164408.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • Salivary gland-type neoplasms of the breast are uncommon and comprise numerous entities analogous to that more commonly seen in salivary glands.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Well established examples of this group include pleomorphic adenoma, adenomyoepithelioma, and adenoid cystic carcinoma.
  • Another family of salivary gland-type mammary epithelial neoplasms is devoid of myoepithelial cells.
  • Key examples include mucoepidermoid carcinoma and acinic cell carcinoma.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


45. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hikino H, Kodama K, Yasui K, Ozaki N, Nagaoka S, Miura H: Intracystic adenomyoepithelioma of the breast--case report and review. Breast Cancer; 2007;14(4):429-33
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracystic adenomyoepithelioma of the breast--case report and review.
  • A case of an intracystic adenomyoepithelioma of the breast mimicking intracystic carcinoma is described.
  • Because the results of fine-needle aspiration cytology of the tumor were interpreted as carcinoma, partial mastectomy with dissection of the axillary nodes was performed.
  • The imaging features of this rare tumor may vary widely, which may result in an incorrect diagnosis of breast carcinoma.
  • While the imaging descriptions of intracystic adenomyoepitheliomas are very limited, this tumor should be considered in the differential diagnosis to avoid unnecessarily aggressive treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Myoepithelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986811.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • A 69-year-old woman without a history of breast neoplasia presented with right nipple pain.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.
  • To the best of our knowledge, this is the first case of basaloid carcinoma to be documented in this anatomic site.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Nipples / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. Resetkova E, Albarracin C, Sneige N: Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature. Am J Surg Pathol; 2006 Jan;30(1):20-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagenous spherulosis of breast: morphologic study of 59 cases and review of the literature.
  • Collagenous spherulosis is a rare benign lesion that can microscopically mimic atypical ductal hyperplasia, cribriform ductal carcinoma in situ, or adenoid cystic carcinoma.
  • This study does not attempt to evaluate the overall incidence of collagenous spherulosis because only cases with an actual diagnosis of collagenous spherulosis in pathology report were reviewed.
  • Collagenous spherulosis was associated with benign lesions of the breast in 41 cases, with atypical ductal hyperplasia in 3 cases, and with lobular carcinoma in situ in 15 cases.
  • In summary, although collagenous spherulosis was mostly associated with benign breast lesions, in our study it was also frequently seen in association with lobular carcinoma in situ.
  • Increased numbers of cases of collagenous spherulosis may be expected in the future as a result of breast cancer-screening programs.
  • Caution is needed not to overinterpret collagenous spherulosis as atypical or ductal carcinoma in situ, especially on core needle biopsy specimens.
  • [MeSH-major] Breast Diseases / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / pathology. Calcinosis. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Collagen / metabolism. Collagen / ultrastructure. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330938.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


49. Jukic DM, Drogowski LM, Davie JR: Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling. Am J Dermatopathol; 2009 Oct;31(7):702-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex spiradenoma/cylindroma confirmed by immunohistochemical and molecular loss-of-heterozygosity profiling.
  • We present a case of spiradenoma/cylindroma with admixed carcinoma of unknown origin, resolved using immunohistochemical and molecular loss-of-heterozygosity (LOH) profiling.
  • The patient, a woman in her mid-70s, initially presented with separate mammary (ductal) carcinomas of the right and left breasts that were treated with radical mastectomies.
  • For 9 years, the patient remained disease free until complaining of a slow-growing skin nodule on the lower back that was excised under clinical suspicion of metastatic mammary carcinoma.
  • Histopathological exam revealed a benign eccrine spiradenoma/cylindroma and an intermixed carcinoma, with a differential diagnosis of either primary eccrine carcinoma or mammary carcinoma metastatic to the spiradenoma/cylindroma.
  • Histological features and immunohistochemical staining favored eccrine carcinoma but not unequivocally; therefore, LOH profiles were performed on archival paraffin block tissue from the 3 neoplastic lesions (4 components).
  • The mammary carcinomas showed disparate LOH at 5 of 7 (right breast) and 4 of 7 (left breast) informative genetic loci, establishing these carcinomas as separate primary neoplasms.
  • Both the spiradenoma/cylindroma and eccrine carcinoma revealed no LOH at the tested loci, establishing the unknown carcinoma as an independent carcinoma arising within a spiradenoma/cylindroma.
  • This neoplasm is referred to in the literature as carcinoma ex spiradenoma/cylindroma and spiradenocylindrocarcinoma.
  • [MeSH-major] Adenoma, Sweat Gland / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Loss of Heterozygosity. Neoplasms, Second Primary / pathology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684510.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G: Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A; 2009 Nov 3;106(44):18740-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.
  • We show that the t(6;9)(q22-23;p23-24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / pathology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Oncogene Proteins, Fusion / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5552-62 [7565707.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jun;10(2):115-21 [7520264.001]
  • [Cites] Oncogene. 1998 Feb 19;16(7):865-72 [9484777.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3017-33 [10378697.001]
  • [Cites] Eur J Oral Sci. 2004 Dec;112(6):545-7 [15560839.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1375-84 [15608679.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):224-35 [15826837.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):470-81 [16444749.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):994-1004 [16762588.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Cell. 2007 Oct 5;131(1):146-59 [17923094.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3072-80 [18059337.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):523-34 [18574464.001]
  • [Cites] Mol Biol Evol. 2008 Oct;25(10):2189-98 [18667440.001]
  • [Cites] Blood. 2009 Jan 15;113(3):505-16 [18818396.001]
  • [Cites] PLoS One. 2009;4(6):e6040 [19557180.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1758-64 [18708755.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1315-23 [12368205.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D552-6 [14681479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5758-62 [2668947.001]
  • [Cites] Oncogene. 1989 Dec;4(12):1419-23 [2687764.001]
  • [Cites] Genes Dev. 1992 Dec;6(12B):2524-35 [1340467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2278-90 [8139533.001]
  • [Cites] Genomics. 1995 Jul 1;28(1):66-73 [7590749.001]
  • (PMID = 19841262.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ969915/ FJ969916/ FJ969917
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYB-NFIB fusion protein, human; 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2773970
  •  go-up   go-down


51. Mendez JE, Fey JV, Cody H, Borgen PI, Sclafani LM: Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology? Ann Surg Oncol; 2005 Jan;12(1):24-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology?
  • BACKGROUND: The widespread use of sentinel lymph node biopsy (SLNB) to replace axillary dissection has broadened the indications for axillary staging in breast cancer.
  • We undertook this study to determine whether SLNB could be omitted in clinically node-negative patients with favorable-histology breast cancer.
  • RESULTS: A total of 196 cases with favorable breast cancer subtypes were identified with a 4.1% (8 of 196) sentinel lymph node (SLN) positivity rate.
  • Each of the histological subtypes included patients with positive SLNs, with the exception of adenoid cystic (n = 4) and secretory (n = 1) breast carcinoma, which were quite rare in our series.
  • CONCLUSIONS: Patients with favorable breast cancer histology have a small risk of axillary SLN metastases.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Jan;12(1):6-8 [15827770.001]
  • (PMID = 15827774.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Kang SP, Martel M, Harris LN: Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol; 2008 Feb;20(1):40-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple negative breast cancer: current understanding of biology and treatment options.
  • PURPOSE OF REVIEW: We have made remarkable advances in treatment of breast cancer with combination chemotherapies, hormonal therapies, and modern targeted therapies.
  • Triple negative breast cancers carry a poor prognosis, however, and they are insensitive to most available hormonal or targeted therapeutic agents thus far developed.
  • A better understanding of pathophysiology, natural history, and currently available treatment options is necessary to improve outcomes of patients with triple negative breast cancer.
  • RECENT FINDINGS: Gene expression profiling has allowed us to classify breast cancers into five subtypes based upon distinctive gene expression signatures.
  • SUMMARY: As we prepare for an era of targeted and individualized medicine, limited understanding of triple negative breast cancer biology presents a challenge in developing novel therapies.
  • Identification of more molecular predictive signatures and their prospective validation will enable us to characterize triple negative breast cancers better and design optimal treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms / metabolism. Carcinoma, Adenoid Cystic / metabolism. Gene Expression Profiling

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Triple Negative Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197004.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Number-of-references] 75
  •  go-up   go-down


53. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol; 2008 Oct;216(2):141-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refinement of breast cancer classification by molecular characterization of histological special types.
  • Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'.
  • These special-type breast cancers are categorized into at least 17 discrete pathological entities; however, whether these also constitute discrete molecular entities remains to be determined.
  • Current therapy decision-making is increasingly governed by the molecular classification of breast cancer (luminal, basal-like, HER2+).
  • We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling.
  • Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level.
  • When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype.
  • Our analysis also revealed that some special types associated with a good prognosis, such as medullary and adenoid cystic carcinomas, display a poor prognosis basal-like transcriptome, providing strong circumstantial evidence that basal-like cancers constitute a heterogeneous group.
  • Taken together, our results imply that the correct classification of breast cancers of special histological type will allow a more accurate prognostication of breast cancer patients and facilitate the identification of optimal therapeutic strategies.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Gene Expression Regulation, Neoplastic


54. Jalali A, Ebrahimi H, Ohadi M, Karimloo M, Shemirani AI, Mohajer B, Khorshid HR: New Variations in the Promoter Regions of Human DOCK4 and RAP1A Genes, and Coding Regions of RAP1A in Sporadic Breast Tumors. Avicenna J Med Biotechnol; 2009 Jul;1(2):117-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New Variations in the Promoter Regions of Human DOCK4 and RAP1A Genes, and Coding Regions of RAP1A in Sporadic Breast Tumors.
  • Breast cancer is the most common cancer among women in developed countries.
  • RAP1A, a tumor suppressor gene, is located at 1p13.3 and plays an important role in the cellular adhesion pathway and is involved in the pathogenesis of breast cancer.
  • In the present study, DNA samples from 64 cases of sporadic breast tumors (referred to Mehrad Hospital in Tehran) were screened using PCR-SSCP method and the number of observed variations compared with the control group (100 normal women).
  • With regard to RAP1A we found a heterozygous mutation, G>A transition in an adenoid cystic carcinoma case, and another heterozygous mutation, G>T transversion in an intraductal papilloma case both at nucleotide +45.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23407849.001).
  • [ISSN] 2008-2835
  • [Journal-full-title] Avicenna journal of medical biotechnology
  • [ISO-abbreviation] Avicenna J Med Biotechnol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3558130
  • [Keywords] NOTNLM ; DOCK4 / Loss of heterozygosity (LOH) / PCR-SSCP / RAP1A / Sporadic breast tumor
  •  go-up   go-down


55. Constantinidou A, Jones RL, Reis-Filho JS: Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther; 2010 Aug;10(8):1197-213
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond triple-negative breast cancer: the need to define new subtypes.
  • Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease.
  • These tumors, however, encompass a wide range of subtypes with varying prognosis, including a number of special types with a good prognosis (e.g., adenoid cystic carcinomas and secretory carcinoma).
  • However, it should be noted that triple-negative breast cancers comprise a heterogeneous group of tumors.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / metabolism. Receptor, ErbB-2 / classification. Receptor, ErbB-2 / deficiency. Receptors, Estrogen / classification. Receptors, Estrogen / deficiency. Receptors, Progesterone / classification. Receptors, Progesterone / deficiency


56. Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N: Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Am J Surg Pathol; 2008 Apr;32(4):544-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
  • Microglandular adenosis (MGA) of the breast is widely known as a benign lesion that can mimic invasive carcinoma.
  • In situ and invasive carcinomas have been described as arising in MGA, but which cases of MGA will progress to carcinoma is unclear.
  • Criteria for distinguishing uncomplicated MGA, MGA with atypia (AMGA), and carcinoma arising in MGA (MGACA) are not standardized.
  • Anderson Cancer Center between 1983 and 2007 that had a diagnosis of MGA.
  • In addition, basal-like component was present in 2 cases, aciniclike in 2, matrix producing in 4, sarcomatoid in 1, and adenoid cystic in 1.
  • One of the AMGA cases recurred as invasive carcinoma in a background of AMGA after 8 years following incomplete excision of the lesion.
  • Three out of 6 MGACA cases (50%) required multiple consecutive resections ending up with mastectomy due to involved margins by invasive or in situ carcinoma.
  • This high incidence of MGACA may not represent the actual frequency of MGAs progressing into carcinoma and is likely due to referral bias in our institution.
  • Nonetheless, the high association of carcinoma with MGA necessitates complete excision of MGA to rule out invasion.
  • Although all the MGACA cases were triple negative and express EGFR (basal-like features), all the cases in our study showed a luminal type of differentiation by CK8/18 expression, indicating that MGACA may not fit well into the current proposed molecular classification of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology. Fibrocystic Breast Disease / pathology. Immunohistochemistry. Precancerous Conditions / pathology
  • [MeSH-minor] Actins / analysis. Adult. Aged. Carcinoma in Situ / pathology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Female. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-kit / analysis. Receptor, Epidermal Growth Factor / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Retrospective Studies. S100 Proteins / analysis. Texas. Time Factors. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300793.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / S100 Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


57. Tsuchiya S, Li F: Electron microscopic findings for diagnosis of breast lesions. Med Mol Morphol; 2005 Dec;38(4):216-24
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electron microscopic findings for diagnosis of breast lesions.
  • The normal mammary gland can be roughly divided into the large duct close to the nipple and the terminal duct located within the lobulus.
  • Heterochromatin is the predominant type of chromatin found in normal mammary glands.
  • If the nuclei of the epithelial cells of normal mammary glands and benign breast lesions are compared with those of malignant breast lesions, the latter are primarily oval or circular in shape whereas the former often show marked notches.
  • The ICL is frequently seen in breast cancers, especially scirrhous carcinoma and lobular carcinoma.
  • Invasive ductal carcinoma can be divided into three types: papillotubular carcinoma, solid-tubular carcinoma, and scirrhous carcinoma.
  • Scirrhous carcinoma can be divided into two subtypes: scirrhous carcinoma in the broader sense of the term (characterized by scirrhous invasion of the stroma by papillotubular carcinoma or solid-tubular carcinoma), and scirrhous carcinoma in the narrower sense of the term (characterized by linear or cluster-like invasion of the stroma without forming ducts).
  • Ultrastructural characteristics of scirrhous carcinoma in the narrow sense are bright cytoplasm (seen in most cells) and euchromatin (seen in all cells of this type of carcinoma).
  • In cases of papillotubular carcinoma, solid-tubular carcinoma, and scirrhous carcinoma in the broad sense, euchromatin is predominant but sporadic cells with heterochromatin are also seen.
  • Adenoid cystic carcinoma and carcinoid tumor of the breast are histological types of breast carcinoma that show characteristic features under an electron microscope.
  • Breast carcinoma shows several ultrastructural characteristics that are useful in differential diagnosis.
  • Therefore, it is advisable to take electron microscopic findings into account when evaluating or diagnosing breast lesions.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / ultrastructure
  • [MeSH-minor] Breast / pathology. Breast / ultrastructure. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1976 Aug;66(2):291-375 [181979.001]
  • [Cites] Acta Pathol Jpn. 1981 Jan;31(1):45-54 [6263041.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):312-8 [8816587.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):967-73 [9269834.001]
  • [Cites] Pathol Annu. 1971;6:1-59 [4342307.001]
  • (PMID = 16378230.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


58. Akiyama F, Horii R: Therapeutic strategies for breast cancer based on histological type. Breast Cancer; 2009;16(3):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategies for breast cancer based on histological type.
  • Breast cancer has various histological types that reflect not only morphological features but also biological characteristics.
  • Therefore, it is not an exaggeration to say that breast cancers of different histological types are different diseases.
  • It is generally accepted that the histological types of breast cancer are clinically significant because they serve as prognosticators and as the common language for improving the accuracy of clinical diagnosis.
  • It is necessary to diagnose breast cancer at the level of not only histological findings by needle biopsy, but also the histologic type based on diagnostic imaging and cytological diagnosis.
  • From the viewpoint of treatment, preoperative drug therapy is being performed more frequently to shrink tumors before breast-conserving therapy or to determine treatment sensitivity.
  • Preoperative drug therapy can be planned by making a histological diagnosis based on needle biopsy findings.
  • Preoperative drug therapy is not indicated for noninvasive carcinoma and papillotubular carcinoma (invasive carcinoma with predominant intraductal components).
  • While complete loss of interstitial infiltration can be expected with solid-tubular carcinoma, it cannot be expected with other histological types, such as invasive lobular carcinoma, adenoid cystic carcinoma, or metaplastic carcinoma (squamous-cell carcinoma and spindle-cell carcinoma).
  • On therapeutic response assessment, the clinical and pathological findings generally match for solid-tubular carcinoma but not for scirrhous carcinoma and invasive lobular carcinoma.
  • With mucinous carcinoma, mucus accumulation can remain, even though most cancer cells disappear; as a result, assessment based on tumor diameter changes is difficult.
  • Histological diagnosis is also significant from the viewpoint of drug sensitivity, and it is important to maintain the accuracy of histological diagnosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479319.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT: In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat; 2007 Sep;104(3):249-55
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo proton magnetic resonance spectroscopy of breast lesions: an update.
  • In vivo proton magnetic resonance spectroscopy ((1)H-MRS) has been demonstrated to be successful in the differentiation of benign and malignant breast lesions in a non-invasive manner by detecting increased levels of composite choline (Cho) compounds.
  • Currently there is molecular evidence of increased Cho metabolism in breast cancer cells.
  • In breast malignancies, (1)H-MRS achieved a high-overall sensitivity (82%).
  • Most test cases were infiltrating duct carcinoma, but infiltrating lobular, medullary, mucinous and adenoid cystic carcinomas were also positive by (1)H-MRS.
  • In ductal carcinoma in situ, the results of (1)H-MRS on the limited number of cases were negative.
  • Most of the assessed benign breast lesions including fibroadenoma, fibrocystic changes, cysts and galactoceles, papilloma, tubular adenoma and phyllodes tumours and were mostly negative by (1)H-MRS, with an overall false positive rate was about 8%.
  • Normal breast tissue was almost always negative by (1)H-MRS, whereas, lactating breast tissue showed positivity with a slightly different spectrum on further analysis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Breast / pathology. Carcinoma / metabolism. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Choline / metabolism. Disease Progression. False Positive Reactions. Female. Humans. Protons. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051424.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protons; N91BDP6H0X / Choline
  • [Number-of-references] 36
  •  go-up   go-down


60. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Myoepithelial carcinoma is the only lesion purely composed of myoepithelial cells.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary


61. Aksu K, Aktaş Z, Aksu F, Orsel O, Demirağ F, Sipit T, Firat Güven S: Spindle cell sarcomatoid carcinoma: first case reported in the trachea. Tuberk Toraks; 2009;57(3):337-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell sarcomatoid carcinoma: first case reported in the trachea.
  • Microscopically, the tumor was composed of fascicular pattern of spindle cells with atypical mitotic figures and nuclear pleomorphism, positively reactive to epithelial membrane antigen supporting a diagnosis of tumour with epithelial differentiation.
  • These findings supported the diagnosis of a spindle cell sarcomatoid carcinoma of trachea.
  • Spindle cell carcinoma cases are reported in many sites, such as head and neck region, larynx, digestive tract, breast, kidney, genital tract, skin and lung, but to our knowledge, not in trachea.
  • Primary malignant tracheal tumours consist mainly of squamous cell carcinoma and adenoid cystic carcinoma and generally have an aggressive course with poor prognosis.
  • We report the first presentation of a spindle cell sarcomatoid carcinoma of trachea together with the clinical course of the patient.
  • [MeSH-major] Carcinoma / pathology. Tracheal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787474.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


62. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol; 2006 Mar;208(4):495-506
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
  • The aim of this study was to assess the morphological characteristics and immunohistochemical profile of breast carcinomas with basal and myoepithelial phenotypes to obtain a better understanding of their biological behaviour and nature.
  • One thousand nine hundred and forty-four invasive breast carcinomas were examined, using tissue microarray (TMA) technology and immunohistochemistry, to identify those tumours that showed basal and myoepithelial phenotypes, and their immunophenotype profile was characterized using a variety of markers.
  • There were positive associations with adenoid cystic growth pattern, loss of tubule formation, marked cellular pleomorphism, poorer Nottingham prognostic index, and development of distant metastasis.
  • Breast cancers with basal and myoepithelial phenotypes are distinct groups of tumours that share some common morphological features and an association with poor prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Myoepithelioma / pathology. Neoplasms, Basal Cell / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429394.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Receptors, Androgen; 68238-35-7 / Keratins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


63. Sartorius C, Gille F, Bédrossian-Pfingsten J, Kempf HG: [Salivary duct carcinoma of the sublingual gland--a case report]. Laryngorhinootologie; 2006 Jul;85(7):517-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salivary duct carcinoma of the sublingual gland--a case report].
  • The salivary duct carcinoma represents a rare variant of the group of adenocarcinomas originated from the salivary glands, especially extremely rare from minor salivary gland origin.
  • A biopsy showed a rare salivary duct carcinoma of comedo-type originated from the left sublingual salivary gland.
  • DISCUSSION: Salivary duct carcinoma is a rare, high-grade malignant epithelial neoplasm, which occurs almost exclusively in the parotid.
  • There is some histologic similarity to intraductal carcinoma of the breast.
  • Differential diagnosis comprises adenoid cystic carcinoma, metastases of other adenocarcinomas, such as the carcinoma of the thyroid gland and the comedocarcinoma of the breast.
  • CONCLUSION: A rare case of a salivary duct carcinoma of sublingual salivary gland origin is presented.
  • [MeSH-major] Carcinoma, Ductal. Salivary Ducts. Salivary Gland Neoplasms. Sublingual Gland
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16586279.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Mahmoud A, Hill DH, O'Sullivan MJ, Bennett MW: Cylindroma of the breast: a case report and review of the literature. Diagn Pathol; 2009;4:30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindroma of the breast: a case report and review of the literature.
  • Cylindroma of the breast is a very rare lesion which is morphological and immunophenotypically identical to benign dermal cylindroma.
  • We report a breast cylindroma in a previously healthy 62 year old female detected through a national breast screening program.
  • The patient had no significant family or past medical history, and specifically no history of breast or skin diseases.
  • At low power the islands of tumour cells formed a "jig-saw" pattern, which is typical of cylindroma, but was present within normal breast parenchyma and no had direct connection with the overlying skin.
  • We discuss the nine previously reported cases and the distinction of breast cylindroma from adenoid cystic carcinoma, the main differential diagnosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725978.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224926
  •  go-up   go-down


65. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res; 2007;9(5):R65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
  • INTRODUCTION: Breast cancer is a heterogeneous group of tumors, and can be subdivided on the basis of histopathological features, genetic alterations and gene-expression profiles.
  • One well-defined subtype of breast cancer is characterized by a lack of HER2 gene amplification and estrogen and progesterone receptor expression ('triple-negative tumors').
  • Hierarchical cluster analysis revealed five distinct subgroups of triple-negative breast cancers.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / genetics. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Gene Amplification. Genes, erbB-2. Humans. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Receptor, Epidermal Growth Factor / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism


66. Guo XL, Wei FC, Sun SZ: [Clinical study of oral and maxillofacial malignancies associated with multiple primary malignant neoplasms]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2006 Feb;24(1):42-4
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinical characteristics, diagnosis and treatment strategy of oral and maxillofacial malignancies in multiple primary malignant neoplasms (MPMNs).
  • Among the 44 cases, there were 24 cases in alimentary and respiratory tract such as oral, pharynx, esophagus, stomach and lung, and 10 cases in salivary gland, breast and female reproductive system.
  • There were 25 cases malignant neoplasms in oral and maxillofacial region where squamous cell carcinoma was the most common pathologic type, secondly adenoid cystic carcinoma.
  • For female patients, breast and female reproductive system should be examined specially.
  • Regular follow-up, early detection, early diagnosis, active and effective treatment can help to improve the survival quality of MPMNs patients.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Carcinoma, Squamous Cell. Mouth Neoplasms. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541654.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Brandt SM, Swistel AJ, Rosen PP: Secretory carcinoma in the axilla: probable origin from axillary skin appendage glands in a young girl. Am J Surg Pathol; 2009 Jun;33(6):950-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory carcinoma in the axilla: probable origin from axillary skin appendage glands in a young girl.
  • Invasive carcinoma in the axilla may arise from skin appendage glands or ectopic breast tissue or it may be a metastasis.
  • Carcinomas of the skin adnexal glands and breast can be difficult to distinguish from each other as they often display the same patterns of growth.
  • Tubular, cribriform, papillary, apocrine, mucinous, and adenoid cystic are histologic types of carcinoma seen in the breast and skin appendage glands.
  • To our knowledge, secretory carcinoma, the most common form of mammary carcinoma in children, has not yet been described as a morphologic pattern of skin adnexal carcinoma, although we cannot exclude the possibility that such a case was reported with a different diagnosis.
  • We report a case of a young girl with secretory carcinoma that seems to have arisen from skin appendage glands in the skin of the axilla in the absence of demonstrable ectopic breast tissue.
  • [MeSH-major] Axilla / pathology. Carcinoma, Skin Appendage / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2010 Aug;34(8):1226-7; author reply 1228 [20631609.001]
  • (PMID = 19342945.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Hansen T, Kunkel M, Weber A, James Kirkpatrick C: Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med; 2006 Mar;35(3):155-60
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated eight patients with bisphosphonate treatment and osteonecrosis (four female, four male; median age: 65.6 years; cancer: multiple myeloma in five patients, breast cancer in three patients; mandibular involvement in five patients, maxillar involvement in three cases), and 10 patients suffering from IORN (all male; median age: 61.3 years; cancer: squamous cell carcinoma in nine patients, adenoid cystic carcinoma in one patient; mandibular involvement in all cases).
  • [MeSH-minor] Actinomyces / isolation & purification. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Bone Density Conservation Agents / adverse effects. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454811.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


69. Fernandez-Flores A, Pol A, Juanes F, Crespo LG: Immunohistochemical phenotype of cutaneous cribriform carcinoma with a panel of 15 antibodies. Med Mol Morphol; 2007 Dec;40(4):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of cutaneous cribriform carcinoma with a panel of 15 antibodies.
  • We report a cribriform carcinoma of the left fossa poplitea in a 62-year-old woman.
  • The patient did not present any symptoms, and the only complaint was the nodule, which was resected for diagnosis.
  • After considering different diagnostic options, we decided that the most appropriate one was cribriform carcinoma, which is an entity described in 1998.
  • The diagnostic criteria, which were provided in the few publications that refer to this entity, helped us to distinguish it from the main mimicker: cystic adenoid carcinoma.
  • Owing to the cribriform pattern of the tumor, we also looked for a metastasis from other sites, mainly breast, vulva, and salivary glands, but all these were clinically excluded.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2005 Jul;58(7):757-61 [15976347.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):75-84 [9426521.001]
  • [Cites] Pathol Annu. 1987;22 Pt 1:83-124 [3033589.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Acta Pathol Jpn. 1991 Dec;41(12):927-32 [1785351.001]
  • [Cites] J Cutan Pathol. 2005 Sep;32(8):577-80 [16115058.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):375-81 [7678545.001]
  • [Cites] J Vet Diagn Invest. 2005 Jul;17(4):389-92 [16131002.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):832-6 [8037297.001]
  • [Cites] Am J Dermatopathol. 1995 Jun;17(3):249-55 [8599433.001]
  • [Cites] Am J Clin Pathol. 1999 May;111(5):709 [10230363.001]
  • [Cites] Arch Dermatol. 1978 Feb;114(2):198-203 [629545.001]
  • [Cites] Dermatology. 1999;199(4):332-7 [10640844.001]
  • [Cites] J Cutan Pathol. 1999 May;26(5):232-41 [10408348.001]
  • (PMID = 18085381.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


70. Whatley WS, Thompson JW, Rao B: Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg; 2006 Mar;134(3):385-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common second malignancies are acute leukemia, bone and soft tissue tumors, and carcinoma of the skin, breast, and thyroid.
  • The pathology of the salivary gland tumors were mucoepidermoid carcinoma (10), adenoid cystic carcinoma (1) , and pleomorphic adenoma (1).
  • The majority of these neoplasms are malignant; mucoepidermoid carcinoma occurs most frequently.
  • [MeSH-major] Neoplasms, Second Primary / diagnosis. Salivary Gland Neoplasms / diagnosis. Survivors
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / surgery. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Male. Neck Dissection. Neoplasms / drug therapy. Neoplasms / radiotherapy. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Factors


71. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol; 2005 May;97(2):337-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapeutic agents targeting COX-2 and c-erbB-2 are used to treat colon and breast cancers.
  • COX-2 protein expression was noted in 140 cases of uterine cervical neoplasm (44.0%): In 26.7% of the cervical intraepithelial neoplasia III (16/60 cases), 37.9% of the microinvasive squamous cell carcinoma (39/103 cases), 51.6% of the invasive squamous cell carcinoma (64/124 cases), and 76.2% of the adenocarcinomas (16/21 cases) (P < 0.005).
  • By contrast, except for one case of adenoid cystic carcinoma, none of the uterine cervical neoplasm expressed c-erbB-2 protein.
  • CONCLUSION: COX-2 may participate in the progression of cervical squamous cell lesions, while the contribution of c-erbB-2 to cervical carcinogenesis is probably small.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Microarray Analysis. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863127.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


72. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human kallikrein 8 protein (KLK8) is expressed in many normal tissues including esophagus, skin, testis, tonsil, kidney, breast, and salivary gland, and is found in biological fluids including breast milk, amniotic fluid, seminal fluid and serum.
  • It has also been shown to be a biomarker and prognostic factor for breast cancer.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Humans. Immunoenzyme Techniques

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


73. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


74. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I: A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer; 2009 Apr 1;115(7):1555-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer.
  • BACKGROUND: The intraoperative evaluation of axillary sentinel lymph nodes (SLNs) allows the surgeon to complete axillary dissection in 1 setting at the time of the primary breast surgery.
  • However, to the authors' knowledge, there is no consensus regarding the optimal method for intraoperative evaluation of SLNs in breast cancer.
  • METHODS: Patients with invasive breast carcinoma who were diagnosed with lymph node-negative disease (based on preoperative clinical and sonographic evaluation with or without fine-needle aspiration of the indeterminate lymph nodes) and who subsequently were scheduled for lymphatic mapping were eligible to participate in this prospective protocol.
  • RESULTS: One hundred patients with invasive mammary carcinoma were accrued to the study.
  • Eighty-five tumors were the ductal type, 8 tumors were lobular, 5 tumors were mixed ductal and lobular, 1 was an adenoid cystic tumor, and 1 tumor was metaplastic carcinoma.
  • Metastatic carcinoma was detected in the SLNs by 1 or more methods, including TI, FS, RCI, and FP, in 20 tumors, which included 12 macrometastases and 8 micrometastases.
  • [MeSH-major] Cytological Techniques / methods. Frozen Sections. Keratins / analysis. Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Axilla. Breast Neoplasms / pathology. Feasibility Studies. Female. Humans. Intraoperative Period. Prospective Studies. Sensitivity and Specificity. Staining and Labeling

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society
  • [CommentIn] Cancer. 2009 Apr 1;115(7):1361-2 [19208425.001]
  • (PMID = 19195040.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


75. Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S: TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Transl Oncol; 2008 Sep;1(3):121-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.
  • Salivary duct carcinomas (SDCs) and adenoid cystic carcinomas (ACCs) are the most aggressive and the most frequent carcinomas of the salivary glands, respectively.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):477-84 [11295066.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2237-45 [11489797.001]
  • [Cites] Prostate. 2000 Oct 1;45(2):140-8 [11027413.001]
  • [Cites] Cancer Lett. 2000 Jun 1;154(1):107-11 [10799746.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5388-94 [10681513.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Head Neck. 2007 Oct;29(10):907-12 [17563907.001]
  • [Cites] Histopathology. 2007 Jul;51(1):114-5 [17532773.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):33-6 [16757202.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Apr;64(4):636-41 [16546643.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):90-8 [16242838.001]
  • [Cites] Oral Oncol. 2005 Oct;41(9):934-9 [16054424.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5108-18 [15870692.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8214-9 [15623596.001]
  • [Cites] Invest New Drugs. 2005 Jan;23(1):31-7 [15528978.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] Int J Biol Markers. 1999 Apr-Jun;14(2):68-72 [10399625.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1887-98 [9717816.001]
  • [Cites] Prostate. 1998 Aug 1;36(3):172-80 [9687989.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):417-27 [10209957.001]
  • [Cites] J Craniomaxillofac Surg. 1997 Dec;25(6):328-34 [9504310.001]
  • [Cites] Ann Anat. 1998 Apr;180(2):157-63 [9587639.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):561-6 [8666365.001]
  • [Cites] Head Neck. 1997 Mar;19(2):126-33 [9059870.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5675-82 [7522962.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Mol Cell Biol. 1989 Jan;9(1):24-33 [2927393.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1545 [15371892.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):294-9 [15236194.001]
  • [Cites] Histopathology. 2004 Mar;44(3):301-2 [14987238.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):938-43 [14871970.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5592-601 [12944907.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(2):207-14 [12908824.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Histopathology. 2003 Apr;42(4):348-56 [12653946.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Hum Pathol. 2002 May;33(5):484-95 [12094373.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):137-44 [11902499.001]
  • [Cites] Pathol Res Pract. 2001;197(9):621-6 [11569926.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1238-43 [11106082.001]
  • (PMID = 18795122.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2533140
  •  go-up   go-down


76. Maillard GF, Garey L: Plastic surgery after ablative cancer surgery. Aesthetic Plast Surg; 2006 Jan-Feb;30(1):47-52
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Humans. Lip Neoplasms / pathology. Lip Neoplasms / surgery. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery. Scalp. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402163.001).
  • [ISSN] 0364-216X
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wang L, Baiocchi RA, Pal S, Mosialos G, Caligiuri M, Sif S: The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol; 2005 Sep;25(18):7953-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BT549 is an invasive human breast carcinoma cell line that lacks expression of BAF57, a key hSWI/SNF subunit that mediates interaction with transcriptional activators and corepressors.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):1899-910 [10688638.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):801-5 [12917691.001]
  • [Cites] Nat Genet. 2000 Jun;25(2):160-5 [10835629.001]
  • [Cites] Cell. 2000 Jul 21;102(2):257-65 [10943845.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6171-7 [11085541.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800 [11095756.001]
  • [Cites] J Biol Chem. 2000 Dec 22;275(51):40463-70 [11013263.001]
  • [Cites] J Cell Physiol. 2001 Jan;186(1):136-45 [11147808.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7475-87 [14559996.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):143-9 [14613035.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):362-76 [14673169.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1937-49 [14676303.001]
  • [Cites] J Cell Biochem. 2004 Apr 15;91(6):1087-98 [15048866.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):171-7 [15173860.001]
  • [Cites] Eur J Neurosci. 2004 Sep;20(5):1177-88 [15341589.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 3;321(4):961-6 [15358121.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):241-9 [15380515.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9630-45 [15485929.001]
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1576-83 [8657132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):492-8 [9435219.001]
  • [Cites] Nature. 1998 Jul 9;394(6689):203-6 [9671307.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2842-51 [9744861.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):6979-91 [9843504.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):247-53 [10078207.001]
  • [Cites] Nat Genet. 2005 Mar;37(3):254-64 [15696166.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1287-95 [11163203.001]
  • [Cites] Genes Dev. 2001 Mar 1;15(5):603-18 [11238380.001]
  • [Cites] EMBO Rep. 2000 Dec;1(6):500-6 [11263494.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3598-603 [11313485.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2852-7 [11053448.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jan;2(1):21-32 [11413462.001]
  • [Cites] Genes Dev. 2001 Aug 15;15(16):2069-82 [11511539.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7787-95 [11604513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Cell. 2002 Feb 22;108(4):475-87 [11909519.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3112-20 [12082626.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):195-9 [12110891.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5975-88 [12138206.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4094-103 [12145209.001]
  • [Cites] Oncogene. 2002 Aug 8;21(34):5193-203 [12149641.001]
  • [Cites] Oncogene. 2002 Sep 19;21(42):6403-12 [12226744.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41038-45 [12192000.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5911-20 [12411508.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):415-25 [12450796.001]
  • [Cites] J Cell Physiol. 2003 Mar;194(3):303-13 [12548550.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):560-6 [12566296.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17876-84 [12637547.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6210-20 [12917342.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):793-6 [12917689.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):797-801 [12917690.001]
  • [Cites] Prog Cell Cycle Res. 2000;4:107-14 [10740819.001]
  • (PMID = 16135788.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA089854; United States / NCI NIH HHS / CA / K01 CA89854
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / SMARCA2 protein, human; 0 / SMARCE1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.6.1.- / SMARCA4 protein, human; EC 3.6.4.- / DNA Helicases
  • [Other-IDs] NLM/ PMC1234311
  •  go-up   go-down


78. Yoshimura T, Sumida T, Liu S, Onishi A, Shintani S, Desprez PY, Hamakawa H: Growth inhibition of human salivary gland tumor cells by introduction of progesterone (Pg) receptor and Pg treatment. Endocr Relat Cancer; 2007 Dec;14(4):1107-16
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic mimicry and similarity in the expression of steroid hormone receptors between salivary gland tumors (SGTs) and breast tumors are well-known phenomena and are occasionally debated in the field of surgical pathology.
  • Progesterone (Pg), one of the female sex steroid hormone, is intimately involved in the development of the mammary gland.
  • Further, it is believed that Pg plays a role in breast cancer progression.
  • In this study, we used ACCM, a human adenoid cystic carcinoma cell line established from the salivary gland, in order to clarify the role of the Pg receptor (PR) on cell proliferation.
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Female. Flow Cytometry. Humans. Neoplasm Invasiveness. Reverse Transcriptase Polymerase Chain Reaction. Telomerase / genetics. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045962.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


79. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR: Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol; 2007 Dec;2(12):1112-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor types included lung (n = 16), adenoid cystic carcinoma (n = 2), prostate (n = 2), sarcoma (n = 2), breast (n = 1), thymus (n = 1), head and neck (n = 1), and gastrointestinal(n = 2).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090584.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Glutamates; 0 / Pyrazines; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 69G8BD63PP / Bortezomib
  •  go-up   go-down


80. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, Harada K, Numata T, Seki N, Sato M, Tanzawa H: WISP-2 expression in human salivary gland tumors. Int J Mol Med; 2006 Apr;17(4):567-73
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We constructed an in-house cDNA microarray carrying 2,201 cDNA clones derived from SGT and oral squamous cell carcinoma cDNA libraries.
  • The genes identified by our microarray system were further analyzed at the mRNA or protein expression level in other types of human cancer cell lines and clinical samples (ten normal salivary glands [NSGs], eleven pleomorphic adenomas, ten adenoid cystic carcinomas and three adenocarcinomas).
  • Of the up-regulated genes, WISP-2, which plays an important role in breast carcinogenesis, was selected for further analyses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525711.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP2 protein, human
  •  go-up   go-down


81. Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A: CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):172-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including breast myoepithelial cells.
  • Surprisingly, adenoid cystic carcinomas and basal cell adenomas were negative in 100% of the cases.
  • The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752720.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


82. Vincent-Salomon A, Macgrogan G, Charaffe-Jauffret E, Jacquemier J, Arnould L: [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. Bull Cancer; 2010 Mar;97(3):357-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Identification en pratique clinique des carcinomes basal-like du sein : des carcinomes "triple zéro/BRCA1-like".
  • Basal-like carcinomas represent 10 to 15% of invasive breast carcinomas and have been identified from gene expression studies.
  • Furthermore, tumors with such a basal-like immunophenotype constitute a heterogeneous group of tumors encompassing good prognosis tumors such as adenoid cystic and juvenile secretory carcinomas.
  • [MeSH-major] Breast Neoplasms / genetics. Carcinoma, Basal Cell / genetics. Gene Expression Profiling / methods. Genes, BRCA1


83. Patel AA, Gupta D, Seligson D, Hattab EM, Balis UJ, Ulbright TM, Kohane IS, Berman JJ, Gilbertson JR, Dry S, Schirripa O, Yu H, Becich MJ, Parwani AV, Shared Pathology Informatics Network: Availability and quality of paraffin blocks identified in pathology archives: a multi-institutional study by the Shared Pathology Informatics Network (SPIN). BMC Cancer; 2007 Feb 28;7:37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each site generated a list of 100 common tumor cases (25 cases each of breast adenocarcinoma, colonic adenocarcinoma, lung squamous carcinoma, and prostate adenocarcinoma) and 100 rare tumor cases (25 cases each of adrenal cortical carcinoma, gastro-intestinal stromal tumor [GIST], adenoid cystic carcinoma, and mycosis fungoides) using a combination of Tumor Registry, laboratory information system (LIS) and/or SPIN-related tools.
  • Retrieval rate (tumor blocks) from all centers for rare tumors was 66% with mean largest tumor size of 1.56 cm; retrieval (tumor blocks) was highest for GIST (72%) and lowest for adenoid cystic carcinoma (58%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1843-9 [11448894.001]
  • [Cites] Mol Diagn. 2000 Dec;5(4):287-99 [11172493.001]
  • [Cites] Arch Pathol Lab Med. 1996 Oct;120(10):909-12 [12046602.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):870-6 [12472280.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:584-8 [14728240.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:937 [14728442.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):176-86 [14983930.001]
  • [Cites] J Urol. 2004 Apr;171(4):1393-401 [15017184.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1115-9 [15026787.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4614-21 [15269132.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):607-10 [15360884.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 1):663-7 [15360896.001]
  • [Cites] Stud Health Technol Inform. 2004;107(Pt 2):1264-7 [15361017.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):1-3 [8646703.001]
  • [Cites] Urology. 1996 Nov;48(5):773-7 [8911524.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1065-76 [9870854.001]
  • [Cites] Science. 1998 Dec 18;282(5397):2165-6 [9890818.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):202-8 [9917130.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):296-300 [10320140.001]
  • [Cites] Clin Lab Med. 2004 Dec;24(4):913-43, vi [15555749.001]
  • [Cites] BMC Cancer. 2005;5:108 [16111498.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:12 [16515714.001]
  • [Cites] AMIA Annu Symp Proc. 2005;:515-9 [16779093.001]
  • [Cites] BMC Cancer. 2006;6:120 [16677389.001]
  • [Cites] Community Genet. 1999;2(2-3):51-60 [11787507.001]
  • (PMID = 17386082.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA091343; United States / NCI NIH HHS / CA / U01 CA091429; United States / NCI NIH HHS / CA / U01CA091429; United States / NCI NIH HHS / CA / P30 CA016042; United States / NCI NIH HHS / CA / U01 CA091343; United States / NCI NIH HHS / CA / UO1CA91338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1810540
  •  go-up   go-down


84. Odashiro M, Lima MG, Miiji LN, Odashiro DN, Carvalho GV, Prates Campos JC, Odashiro AN: Infiltrating syringomatous adenoma of the nipple. Breast J; 2009 Jul-Aug;15(4):414-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, it must be distinguished from florid papillomatosis, adenosquamous carcinoma, adenoid cystic carcinoma and sclerosing syringomatous carcinoma.
  • [MeSH-major] Adenoma / surgery. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Nipples / pathology. Syringoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19470133.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Miettinen M, Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol; 2005 Sep;13(3):205-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other KIT-positive normal cells include epithelial cells in skin adnexa, breast, and subsets of cerebellar neurons.
  • Also, KIT is expressed in pulmonary and other small cell carcinomas, adenoid cystic carcinoma, renal chromophobe carcinoma, thymic, and some ovarian and few breast carcinomas.
  • KIT tyrosine kinase inhibitors such as imatinib mesylate are the generally accepted treatment of metastatic GISTs, and their availability has prompted an active search for other treatment targets among KIT-positive tumors such as myeloid leukemias and small cell carcinoma of the lung, with variable and often nonconvincing results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16082245.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 239
  •  go-up   go-down


86. Grunert JH, Kreipe HH: [Morphologic and differential diagnosis of an adenoid-cystic carcinoma of the breast]. Rofo; 2007 Nov;179(11):1193-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and differential diagnosis of an adenoid-cystic carcinoma of the breast].
  • [Transliterated title] Morphologie und Differenzialdiagnose des mammären adenoid-zystischen Karzinoms.
  • [MeSH-major] Breast Neoplasms / surgery. Breast Neoplasms / ultrasonography. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Adenoid Cystic / ultrasonography
  • [MeSH-minor] Biomarkers / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948198.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


87. Mardi K, Sharma J, Garg R: Cytodiagnosis of adenoid cystic carcinoma of the breast. Indian J Pathol Microbiol; 2007 Jul;50(3):626-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnosis of adenoid cystic carcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883166.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


88. Alis H, Yigitbas H, Kapan S, Kalayci M, Kilic G, Aygun E: Multifocal adenoid cystic carcinoma of the breast: an unusual presentation. Can J Surg; 2008 Apr;51(2):E36-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal adenoid cystic carcinoma of the breast: an unusual presentation.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Adenoid Cystic / surgery
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Breast / pathology. Carcinoma, Ductal / diagnosis. Carcinoma, Ductal / pathology. Carcinoma, Ductal / surgery. Diagnosis, Differential. Female. Humans. Mammography. Mastectomy, Radical. Ultrasonography, Mammary

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2005 Oct;93(3):189-90 [16142443.001]
  • [Cites] Clin Lab Med. 2005 Dec;25(4):761-75, vii [16308090.001]
  • [Cites] Ann Diagn Pathol. 2005 Jun;9(3):157-9 [15944959.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):470-6 [2543695.001]
  • [Cites] Breast. 2003 Feb;12(1):75-7 [14659359.001]
  • [Cites] Diagn Cytopathol. 2004 Apr;30(4):271-4 [15048965.001]
  • [Cites] Hum Pathol. 1987 Dec;18(12):1276-81 [2824330.001]
  • [Cites] Am J Surg. 2002 Jun;183(6):646-9 [12095593.001]
  • (PMID = 18377738.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2386339
  •  go-up   go-down


89. Youk JH, Kim MJ, Kim EK, Lee JY, Oh KK, Park BW: Recurrence of adenoid cystic carcinoma in the breast after lumpectomy and adjuvant therapy. J Ultrasound Med; 2006 Jul;25(7):921-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of adenoid cystic carcinoma in the breast after lumpectomy and adjuvant therapy.
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms / ultrasonography. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Adenoid Cystic / ultrasonography. Mastectomy, Segmental. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798905.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Torrão MM, da Costa JM, Ferreira E, da Silva MV, Paiva I, Lopes C: Adenoid cystic carcinoma of the breast. Breast J; 2007 Mar-Apr;13(2):206
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Breast / pathology. Female. Humans

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319868.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Page DL: Adenoid cystic carcinoma of breast, a special histopathologic type with excellent prognosis. Breast Cancer Res Treat; 2005 Oct;93(3):189-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of breast, a special histopathologic type with excellent prognosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Breast Cancer Res Treat. 2004 Oct;87(3):225-32 [15528965.001]
  • (PMID = 16142443.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Sarnaik AA, Meade T, King J, Acs G, Hoover S, Cox CE, Carter WB, Laronga C: Adenoid cystic carcinoma of the breast: a review of a single institution's experience. Breast J; 2010 Mar-Apr;16(2):208-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the breast: a review of a single institution's experience.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030648.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Letter; Review
  • [Publication-country] United States
  • [Number-of-references] 5
  •  go-up   go-down


93. Sherigar JM, Finnegan J, McManus D, Lioe TF, Spence RA: Extra salivary adenoid cystic carcinoma; report of two cases. Ulster Med J; 2006 Sep;75(3):223-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra salivary adenoid cystic carcinoma; report of two cases.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1993;9(2):184-7 [8390344.001]
  • [Cites] Australas Radiol. 1994 Nov;38(4):324-5 [7993263.001]
  • [Cites] Cytopathology. 1997 Feb;8(1):31-9 [9068954.001]
  • [Cites] Diagn Cytopathol. 1997 May;16(5):442-5 [9143847.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1679-83 [9843312.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):455-8 [15816611.001]
  • [Cites] Breast Cancer. 2001;8(1):84-9 [11180772.001]
  • [Cites] Am J Ophthalmol. 2001 Feb;131(2):281-3 [11228319.001]
  • [Cites] Cytopathology. 2001 Aug;12(4):266-9 [11488877.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jun;101(6):302-6 [193456.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):470-6 [2543695.001]
  • [Cites] Arch Surg. 1992 Feb;127(2):233-5 [1311551.001]
  • (PMID = 16964816.001).
  • [ISSN] 0041-6193
  • [Journal-full-title] The Ulster medical journal
  • [ISO-abbreviation] Ulster Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Northern Ireland
  • [Other-IDs] NLM/ PMC1891784
  •  go-up   go-down


94. Pahwa R, Jain S: Extracellular hyaline material in breast smears: how to interpret? Breast J; 2010 Jul-Aug;16(4):431-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular hyaline material in breast smears: how to interpret?
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Collagen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459433.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-34-5 / Collagen
  •  go-up   go-down


95. Hill P, Cawson J: Collagenous spherulosis with lobular carcinoma in situ: a potential diagnostic pitfall. Pathology; 2007 Jun;39(3):361-3
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagenous spherulosis with lobular carcinoma in situ: a potential diagnostic pitfall.
  • [MeSH-major] Breast Diseases / complications. Breast Diseases / diagnosis. Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Carcinoma, Lobular / complications. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Calcinosis / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Intraductal, Noninfiltrating / complications. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Mammography. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558867.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


96. Quibell R, Baker L: Nicotine withdrawal and nicotine replacement in the palliative care setting. J Pain Symptom Manage; 2005 Sep;30(3):205-7
Hazardous Substances Data Bank. NICOTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / complications. Breast Neoplasms / therapy. Carcinoma, Adenoid Cystic / complications. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Renal Cell / complications. Carcinoma, Renal Cell / therapy. Female. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / therapy. Lung Neoplasms / complications. Lung Neoplasms / therapy. Parotid Neoplasms / complications. Parotid Neoplasms / therapy. Smoking / epidemiology

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183003.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nicotinic Agonists; 6M3C89ZY6R / Nicotine
  •  go-up   go-down






Advertisement